AZA-SUBSTITUTED INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Abstract

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, aza-substituted triterpenoid compounds that possess unique antiviral activity are provided as HIV maturation inhibitors, as represented by compounds of Formula I:

##STR00001##

These compounds are useful for the treatment of HIV and AIDS.

Claims

1. (canceled)

2. A compound or salt as claimed in claim 28, wherein R.sub.1 is isopropenyl.

3-9. (canceled)

10. A compound or salt as claimed in claim 28, wherein Y is COOH.

11-17. (canceled)

18. A compound or salt as claimed in claim 28, wherein W is CH.sub.2OR.sub.2.

19.-23. (canceled)

24. A compound or salt as claimed in claim 28 wherein W is CH.sub.2NR.sub.26R.sub.27.

25-27. (canceled)

28. A compound of Formula II, or a pharmaceutically acceptable salt thereof: ##STR00185## wherein R.sub.1 is isopropenyl or isopropyl; X is a phenyl or heteroaryl ring substituted with A, wherein A is at least one member selected from H, halogen, hydroxyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.1-6 alkoxy, and COOR.sub.2; alternatively, X is selected from a single bond, C.sub.1-6alkyl-, C.sub.1-6alkylaryl-, C.sub.2-6alkenyl-, C.sub.2-6alkenylaryl-, CO, SO.sub.2, C.sub.1-6alkylCO, C.sub.2-6alkenylCO, COalkylsubstituted C.sub.1-6 alkyl-, COspiroalkylsubstitutedC.sub.1-6 alkyl-, COarylsubstitutedC.sub.1-6 alkyl-, COarylsubstituted C.sub.2-6 alkenyl-, COheteroaryl-, COaryl-, COC.sub.1-6 alkylaryl-, COC.sub.1-6 alkylheteroaryl-, COalkylsubstituted C.sub.3-6 cycloalkyl-, COC.sub.2-6 alkenylaryl-, COC.sub.1-6 alkyl(NHR.sub.0), C.sub.1-6 alkyl(CONHR.sub.0), (COCO)NR.sub.0SO.sub.2, SO.sub.2C.sub.1-6 alkyl-, SO.sub.2alkylsubstitutedC.sub.1-6 alkyl-, SO.sub.2arylsubstituted C.sub.1-6 alkyl-, SO.sub.2C.sub.1-6 alkylaryl-, SO.sub.2C.sub.2-6 alkenylaryl-, SO.sub.2aryl-, SO.sub.2arylC.sub.1-6alkyl-, SO.sub.2arylC.sub.2-6alkenyl-, SO.sub.2heteroaryl-, -heteroaryl-Q.sub.0- and -aryl-Q.sub.0-; Q.sub.0 is selected from C.sub.1-6 alkyl, -halo, CF.sub.3 and OC.sub.1-6 alkyl, R.sub.0 is H, C.sub.1-6 alkyl, -alkylsubstituted C.sub.1-6 alkyl, -alkylsubstituted(C.sub.1-6)COOR.sub.6, -spiroalkylsubstituted(C.sub.1-6)COOR.sub.6, or -aryl substituted C.sub.1-6 alkyl; R.sub.2 is H, C.sub.1-6 alkyl, -alkylsubstituted C.sub.1-6 alkyl, or-arylsubstituted C.sub.1-6 alkyl; Y is selected from COOR.sub.2, C(O)NR.sub.2SO.sub.2R.sub.3, C(O)NHSO.sub.2NR.sub.2R.sub.2, NR.sub.2SO.sub.2R.sub.2, SO.sub.2NR.sub.2R.sub.2, C.sub.3-6 cycloalkyl-COOR.sub.2, C.sub.2-6 alkenyl-COOR.sub.2, C.sub.2-6 alkynyl-COOR.sub.2, C.sub.1-6 alkyl-COOR.sub.2, NHC(O)(CH.sub.2).sub.pCOOR.sub.2, SO.sub.2NR.sub.2C(O)R.sub.2, -tetrazole, and CONHOH, wherein p is 1-6; alternatively, Y is selected from a phenyl or heteroaryl ring, optionally further substituted with 1 to 3 substituents selected from H, -halo, -hydroxyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, COOR.sub.2, CN, NO.sub.2, CF.sub.3, SO.sub.2, NR.sub.26R.sub.27, CONR.sub.26R.sub.27, and SO.sub.2NR.sub.26R.sub.27; alternatively, X-Y is selected from ##STR00186## R.sub.3 is C.sub.1-6 alkyl or -alkylsubstituted C.sub.1-6 alkyl; Z is selected from CO and CH.sub.2; W is selected from CH.sub.2OR.sub.2, COOR.sub.2, NR.sub.4R.sub.5, CONR.sub.26R.sub.27, CH.sub.2NR.sub.26R.sub.27, NR.sub.4COR.sub.6, NR.sub.4C(O)NR.sub.4R.sub.5, and NR.sub.4COOR.sub.6; R.sub.4 is selected from H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-C(OR.sub.3).sub.2C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl, C.sub.1-6 alkyl-Q.sub.1, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl-Q.sub.1, aryl, heteroaryl, substituted heteroaryl, COR.sub.6, COCOR.sub.6, SO.sub.2R.sub.7, and SO.sub.2NR.sub.2R.sub.2, wherein Q.sub.1 is selected from C.sub.3-10 carbocycle, substituted C.sub.3-10 carbocycle, C.sub.3-10 heterocycle, substituted C.sub.3-10 heterocycle, aryl, heteroaryl, substituted heteroaryl, halogen, CF.sub.3, OR.sub.2, COOR.sub.2, NR.sub.8R.sub.9, CONR.sub.10R.sub.11 and SO.sub.2R.sub.7; alternatively, R.sub.4 is selected from C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-heteroaryl, C.sub.1-6 alkyl-substituted heteroaryl, C.sub.1-6 alkyl-NR.sub.6R.sub.7, C.sub.1-6 alkyl-CONR.sub.8R.sub.9, C.sub.3-6 cycloalkyl-CONR.sub.8R.sub.9, C.sub.3-6 cycloalkyl-(CH.sub.2).sub.1-3NR.sub.6R.sub.7, (CH.sub.2).sub.1-3C.sub.3-6 cycloalkyl-NR.sub.6R.sub.7, (CH.sub.2).sub.1-3C.sub.3-6 cycloalkyl-(CH.sub.2).sub.1-3NR.sub.6R.sub.7; C.sub.1-6 alkyl-Q.sub.1, C.sub.3-6 cycloalkyl-Q.sub.1, COR.sub.10, SO.sub.2R.sub.3, and ##STR00187## wherein Q.sub.1 is selected from-hydroxy, COOR.sub.2, -halo, and SO.sub.2R.sub.a; R.sub.a is C.sub.1-6 alkyl, NR.sub.2R.sub.2, ##STR00188## R.sub.b is H, C.sub.1-6 alkyl, COR.sub.3, SO.sub.2R.sub.3, SONR.sub.3R.sub.3, R.sub.5 is selected from H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 alkylsubstituted alkyl, C.sub.1-6 alkyl-NR.sub.8R.sub.9, COR.sub.6, COCOR.sub.6, SO.sub.2R.sub.7 and SO.sub.2NR.sub.2R.sub.2; with the proviso that only one of R.sub.4 or R.sub.5 can be selected from COR.sub.6, COCOR.sub.6, SO.sub.2R.sub.7 and SO.sub.2NR.sub.2R.sub.2; R.sub.6 is selected from H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-substitutedalkyl, C.sub.3-6 cycloalkyl, C.sub.3-6 substituted cycloalkyl-Q.sub.2, C.sub.1-6 alkyl-Q.sub.2, C.sub.1-6 alkyl-substitutedalkyl-Q.sub.2, C.sub.3-6 cycloalkyl-Q.sub.2, aryl-Q.sub.2, NR.sub.13R.sub.14, and OR.sub.15; wherein Q.sub.2 is selected from C.sub.3-10 carbocycle, substituted C.sub.3-10 carbocycle, C.sub.3-10 heterocycle, substituted C.sub.3-10 heterocycle, aryl, heteroaryl, substituted heteroaryl, OR.sub.2, COOR.sub.2, NR.sub.8R.sub.9, SO.sub.2R.sub.7, CONHSO.sub.2R.sub.3, and CONHSO.sub.2NR.sub.2R.sub.2; R.sub.7 is selected from C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, C.sub.3-6 cycloalkyl, aryl, and heteroaryl; R.sub.8 and R.sub.9 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, C.sub.1-6 alkyl-Q.sub.2, and COOR.sub.3, alternatively R.sub.8 and R.sub.9 are taken together with the adjacent N to form a cycle selected from: ##STR00189## ##STR00190## V is selected from CR.sub.24R.sub.25, SO.sub.2, O and NR.sub.12; M is selected from CHR.sub.24R.sub.25, NR.sub.26R.sub.27, SO.sub.2R.sub.7, SO.sub.2NR.sub.3R.sub.3 and OH; with the proviso that only one of R.sub.8 or R.sub.9 can be COOR.sub.3; R.sub.10 and R.sub.11 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl and C.sub.3-6 cycloalkyl, alternatively R.sub.10 and R.sub.11 are taken together with the adjacent N to form a cycle such as ##STR00191## R.sub.12 is selected from C.sub.1-6 alkyl, C.sub.1-6 alkyl-OH; C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl,-C.sub.3-6 cycloalkyl, COR.sub.7, COONR.sub.22R.sub.23, SORT, and SONR.sub.24R.sub.25; R.sub.13 and R.sub.14 are independently selected from H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-Q.sub.3, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl-Q.sub.3 and C.sub.1-6 substituted alkyl-Q.sub.3, alternatively R.sub.13 and R.sub.14 are taken together with the adjacent N to form a cycle selected from: ##STR00192## Q.sub.3 is selected from heteroaryl, substituted heteroaryl, NR.sub.20R.sub.21, CONR.sub.2R.sub.2, COOR.sub.2, OR.sub.2, and SO.sub.2R.sub.3; R.sub.15 is selected from C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-Q.sub.3, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl-Q.sub.3 and C.sub.1-6 substituted alkyl-Q.sub.3, R.sub.16 is selected from H, C.sub.1-6 alkyl, NR.sub.2R.sub.2, and COOR.sub.3; R.sub.17 is selected from H, C.sub.1-6 alkyl, COOR.sub.3, and aryl; R.sub.18 is selected from COOR.sub.2 and C.sub.1-6 alkyl-COOR.sub.2; R.sub.19 is selected from H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-Q.sub.4, COR.sub.3, COOR.sub.3, wherein Q.sub.4 is selected from NR.sub.2R.sub.2 and OR.sub.2; R.sub.20 and R.sub.21 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 substituted alkyl-OR.sub.2, and COR.sub.3, alternatively R.sub.20 and R.sub.21 are taken together with the adjacent N to form a cycle selected from ##STR00193## with the proviso that only one of R.sub.20 or R.sub.21 can be COR.sub.3, R.sub.22 and R.sub.23 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, and C.sub.1-6 cycloalkyl, or R.sub.22 and R.sub.23 are taken together with the adjacent N to form a cycle selected from ##STR00194## R.sub.24 and R.sub.25 are independently from the group of H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-Q.sub.5, C.sub.1-6 cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, and Q.sub.5 is selected from halogen and SO.sub.2R.sub.3, R.sub.26 and R.sub.27 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, C.sub.1-6 alkyl-Q.sub.2, and ##STR00195## or alternatively R.sub.26 and R.sub.27 are taken together with the adjacent N to form a cycle selected from: ##STR00196##

29. (canceled)

30. A pharmaceutical composition comprising a compound or salt of claim 28 and a pharmaceutically acceptable carrier.

31. The composition of claim 30 further comprising a at least one other agent used for treatment of AIDS or HIV infection selected from nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors, and a pharmaceutically acceptable carrier.

32. The composition of claim 30 wherein the other agent is dolutegravir.

33. A method for treating HIV infection comprising administering a compound of claim 28, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.

34. The method of claim 33 further comprising administering at least one other agent used for treatment of AIDS or HIV infection selected from nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors.

35. The method of claim 34 wherein the other agent is dolutegravir.

36. The method of claim 34 wherein the other agent is administered to the patient prior to, simultaneously with, or subsequently to the compound or salt of claim 28.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0058] The singular forms a, an, and the include plural reference unless the context dictates otherwise.

[0059] Unless otherwise expressly set forth elsewhere in the application, the following terms shall have the following meanings:

[0060] Alkenyl means a straight or branched alkyl group comprised of 2 to 10 carbons with at least one double bond and optionally substituted with 0-3 halo or alkoxy group.

[0061] Alkenyloxy means an alkenyl group attached to the parent structure by an oxygen atom.

[0062] Alkoxy means an alkyl group attached to the parent structure by an oxygen atom.

[0063] Alkoxycarbonyl means an alkoxy group attached to the parent structure by a carbonyl moiety.

[0064] Alkyl means a straight or branched saturated hydrocarbon comprised of 1 to 10 carbons, and preferably 1 to 6 carbons.

[0065] Alkylthioxy means an alkyl group attached to the parent structure through a sulfur atom.

[0066] Alkynyl means a straight or branched alkyl group comprised of 2 to 10 carbons, preferably 2 to 6 carbons, containing at least one triple bond and optionally substituted with 0-3 halo or alkoxy group.

[0067] Aryl mean a carbocyclic group comprised of 1-3 rings that are fused and/or bonded and at least one or a combination of which is aromatic. The non-aromatic carbocyclic portion, where present, will be comprised of C.sub.3 to C.sub.7 alkyl group. Examples of aromatic group include, but are not limited to, phenyl, biphenyl, cyclopropylphenyl, indane, naphthalene, and tetrahydronaphthalene. The aryl group can be attached to the parent structure through any substitutable carbon atom in the group.

[0068] Arylalkyl is a C.sub.1-C.sub.5 alkyl group attached to 1 to 2 aryl groups and linked to the parent structure through the alkyl moiety. Examples include, but are not limited to, (CH.sub.2).sub.nPh with n is 1-5, CH(CH.sub.3)Ph, CH(Ph).sub.2.

[0069] Aryloxy is an aryl group attached to the parent structure by oxygen.

[0070] Azaindole means one of the CH moieties in the 6-member ring of an indole is substituted with a nitrogen atom.

[0071] Azaindoline means one of the aromatic CH moieties of an indoline is substituted with a nitrogen atom.

[0072] Azatetrahydroquinoline means any aromatic CH moiety of tetrahydroquinoline is substituted with a nitrogen atom.

[0073] Benzyloxy means a benzyl group is attached to the parent structure through an oxygen atom. The phenyl group of the benzyl moiety could be optionally substituted by 1-3 moieties independently selected from alkyl, alkoxy, halo, haloalkyl, haloalkoxy and cyano. C.sub.x-C.sub.7 notation indicates a structural element comprised of carbons numbering between x and y. For example, C.sub.5-C.sub.10 bicycloalkyl means a bicyclic ring system comprised of 5 to 10 carbons, where the rings are attached in a fused, spiro or bridged manner; an example of C.sub.5-C.sub.10 bicycloalkyl include, but is not limited to, bicyclo[2.2.2]octane. Similarly, C.sub.3-C.sub.4 cycloalkyl is a subset of monocyclic ring system comprised of 3 to 4 carbons.

[0074] Cycloalkyl means a monocyclic ring system comprised of 3 to 7 carbons.

[0075] Cyano refers to CN.

[0076] Diazaindole means any two CH moieties in the 6-member ring of an indole are substituted with nitrogen atoms.

[0077] Diazaindoline means any two aromatic CH moieties of an indoline are substituted with a nitrogen atom.

[0078] Diazatetrahydroquinoline means any two aromatic CH moieties of tetrahydroquinoline are substituted with nitrogen atoms.

[0079] Halo or halogen refers to F, Cl, Br, or I.

[0080] Haloalkyl means an alkyl group substituted by any combination of one to six halogen atoms.

[0081] Haloalkoxy or Haloalkyloxy means a haloalkyl group attached to the parent structure through an oxygen atom.

[0082] Hydroxy refers to OH.

[0083] Heteroaryl is a subset of heterocyclic group as defined below and is comprised of 1-3 rings where at least one or a combination of which is aromatic and that the aromatic group contains at least one atom chosen from a group of oxygen, nitrogen or sulfur.

[0084] Heterocyclyl or heterocyclic means a cyclic group of 1-3 rings comprised of carbon and at least one other atom selected independently from oxygen, nitrogen and sulfur. The rings could be bridged, fused and/or bonded, through a direct or spiro attachment, with the option to have one or a combination thereof be aromatic. Examples include, but are not limited to, azaindole, azaindoline, azetidine, benzimidazole, benzodioxolyl, benzoisothiazole, benzothiazole, benzothiadiazole, benzothiophene, benzoxazole, carbazole, chroman, dihalobezodioxolyl, dihydrobenzofuran, dihydrobenzo[1,4]oxazine, 1,3-dihydrobenzo[c]thiophene 2,2-dioxide, 2,3-dihydrobenzo[d]isothiazole 1,1-dioxide, 3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazine, 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine and its regioisomeric variants, 6,7-dihydro-5H-pyrrolo[2,3-b]pyrazine and its regioisomeric variants, furanylphenyl, imidazole, imidazo[1,2-a]pyridine, indazole, indole, indoline, isoquinoline, isoquinolinone, isothiazolidine 1,1-dioxide, morpholine, 2-oxa-5-azabicyclo[2.2.1]heptane, oxadiazole-phenyl, oxazole, phenylaztidine, phenylindazole, phenylpiperidine, phenylpiperizine, phenyloxazole, phenylpyrrolidine, piperidine, pyridine, pyridinylphenyl, pyridinylpyrrolidine, pyrimidine, pyrimidinylphenyl, pyrrazole-phenyl, pyrrolidine, pyrrolidin-2-one, 1H-pyrazolo[4,3-c]pyridine and its regioisomeric variants, pyrrole, 5H-pyrrolo[2,3-b]pyrazine, 7H-pyrrolo[2,3-d]pyrimidine and its regioisomeric variants, quinazoline, quinoline, quinoxaline, tetrahydroisoquinoline, 1,2,3,4-tetrahydro-1,8-naphthyridine, tetrahydroquinoline, 4,5,6,7-tetrahydrothieno[3,2-c]pyridine, 1,2,5-thiadiazolidine 1,1-dioxide, thiophene, thiophenylphenyl, triazole, or triazolone. Unless otherwise specifically set forth, the heterocyclic group can be attached to the parent structure through any suitable atom in the group that results in a stable compound.

[0085] It is understood that a subset of the noted heterocyclic examples encompass regioisomers. For instance, azaindole refers to any of the following regioisomers: 1H-pyrrolo[2,3-b]pyridine, 1H-pyrrolo[2,3-c]pyridine, 1H-pyrrolo[3,2-c]pyridine, and 1H-pyrrolo[3,2-b]pyridine. In addition the regioisomer variants notation as in, for example, 5H-pyrrolo[2,3-b]pyrazine and its regioisomeric variants would also encompass 7H-pyrrolo[2,3-d]pyrimidine, 7H-pyrrolo[2,3-c]pyridazine, 1H-pyrrolo[2,3-d]pyridazine, 5H-pyrrolo[3,2-c]pyridazine, and 5H-pyrrolo[3,2-d]pyrimidine. Similarly, 6,7-dihydro-5H-pyrrolo[2,3-b]pyrazine and its regioisomeric variants would encompass 6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidine and 6,7-dihydro-5H-pyrrolo[2,3-c]pyridazine. It is also understood that the lack of regioisomeric variants notation does not in any way restrict the claim scope to the noted example only.

[0086] Heterocyclylalkyl is a heterocyclyl moiety attached to the parent structure through C.sub.1-C.sub.5 alkyl group. Examples include, but are not limited to, (CH.sub.2).sub.nR.sup.Z or CH(CH.sub.3)(R.sup.Z) where n is 1-5 and that R.sup.Z is chosen from benzimidazole, imidazole, indazole, isooxazole, phenyl-pyrazole, pyridine, quinoline, thiazole, triazole, triazolone, oxadiazole.

[0087] Triterpene or triterpenoid means a class of compounds based on three terpene units, which are in turn each based on two isoprene units. Triterpenes exist in a large variety of structures and can be broadly divided according to the number of rings present. The aza-substituted triterpenoids of the present invention are in general pentacyclic structures, i.e. having five rings, with one of these rings (the A ring as per the IUPAC naming convention) being nitrogen-substituted, as per Formula I. The following structure of cholesterol (a 4-ring terpenoid) illustrates the IUPAC ring naming convention.

##STR00014##

Cholesterol and IUPAC Ring Naming Convention

[0088] Tetrahydroquinoline means 1,2,3,4-tetrahydroquinoline.

[0089] Substituents which are illustrated by chemical drawing to bond at variable positions on a multiple ring system (for example a bicyclic ring system) are intended to bond to the ring where they are drawn to append. Parenthetic and multiparenthetic terms are intended to clarify bonding relationships to those skilled in the art. For example, a term such as ((R)alkyl) means an alkyl substituent further substituted with the substituent R.

[0090] Also, the X substituent which is connected to the Y substituent and the nitrogen of the aza ring, as in e.g., Formula I,

##STR00015##

is understood that it can be connected in either direction, unless indicated otherwise. For example, X being selected from C.sub.1-6alkylaryl-, means that the substituent, as illustrated for C.sub.1-6alkyl being (CH.sub.2).sub.6 and aryl being phenyl, can be connected in either orientation as shown immediately below.

##STR00016##

[0091] Those terms not specifically set forth herein shall have the meaning which is commonly understood and accepted in the art.

[0092] The invention includes all pharmaceutically acceptable salt forms of the compounds. Pharmaceutically acceptable salts are those in which the counter ions do not contribute significantly to the physiological activity or toxicity of the compounds and as such function as pharmacological equivalents. These salts can be made according to common organic techniques employing commercially available reagents. Some anionic salt forms include acetate, acistrate, besylate, bromide, chloride, citrate, fumarate, glucouronate, hydrobromide, hydrochloride, hydroiodide, iodide, lactate, maleate, mesylate, nitrate, pamoate, phosphate, succinate, sulfate, tartrate, tosylate, and xinofoate. Some cationic salt forms include ammonium, aluminum, benzathine, bismuth, calcium, choline, diethylamine, diethanolamine, lithium, magnesium, meglumine, 4-phenylcyclohexylamine, piperazine, potassium, sodium, tromethamine, and zinc.

[0093] Some of the compounds of the invention exist in stereoisomeric forms. The invention includes all stereoisomeric forms of the compounds including enantiomers and diastereomers. Methods of making and separating stereoisomers are known in the art. The invention includes all tautomeric forms of the compounds. The invention includes atropisomers and rotational isomers.

[0094] The invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium and tritium. Isotopes of carbon include .sup.13C and .sup.14C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed. Such compounds may have a variety of potential uses, for example as standards and reagents in determining biological activity. In the case of stable isotopes, such compounds may have the potential to favorably modify biological, pharmacological, or pharmacokinetic properties.

[0095] For the sake of efficiency some ring structures are shown with a variable number of members in the ring. For example, the following ring substituent

##STR00017##

having the parenthetical ( ).sub.1,2 is intended to encompass both a single carbon group, (CH.sub.2), and a two carbon group, (CH.sub.2CH.sub.2). The intended ring structures could individually be depicted as:

##STR00018##

[0096] The compounds of the invention also include prodrugs. The term prodrug as used herein encompasses both the term prodrug esters and the term prodrug ethers.

[0097] The common numbering system for the general core of the pentacyclic triterpenoid compounds of the present invention is shown below for an illustrative triterpene: betulin. This numbering system is in accordance with IUPAC rules.

##STR00019##

[0098] In an aspect of the invention, there is provided a compound of Formula I, including pharmaceutically acceptable salts thereof:

##STR00020##

wherein n is 1 or 2; [0099] R.sub.1 is isopropenyl or isopropyl; [0100] X is a phenyl or heteroaryl ring substituted with A, wherein A is at least one member selected from H, halogen, hydroxyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.1-6 alkoxy, and COOR.sub.2; [0101] alternatively, X is selected from a single bond, C.sub.1-6alkyl-, C.sub.1-6alkylaryl-, C.sub.2-6alkenyl-, C.sub.2-6alkenylaryl-, CO, SO.sub.2, C.sub.1-6alkylCO, C.sub.2-6alkenylCO, COalkylsubstituted C.sub.1-6 alkyl-, COspiroalkylsubstitutedC.sub.1-6 alkyl-, COarylsubstitutedC.sub.1-6 alkyl-, COarylsubstituted C.sub.2-6 alkenyl-, COheteroaryl-, COaryl-, COC.sub.1-6 alkylaryl-, COC.sub.1-6 alkylheteroaryl-, COalkylsubstituted C.sub.3-6 cycloalkyl-, COC.sub.2-6 alkenylaryl-, COC.sub.1-6 alkyl(NHR.sub.0), C.sub.1-6 alkyl(CONHR.sub.0), (COCO)NR.sub.0SO.sub.2, SO.sub.2C.sub.1-6 alkyl-, SO.sub.2alkylsubstitutedC.sub.1-6 alkyl-, SO.sub.2arylsubstituted C.sub.1-6 alkyl-, SO.sub.2C.sub.1-6 alkylaryl-, SO.sub.2C.sub.2-6 alkenylaryl-, SO.sub.2aryl-, SO.sub.2arylC.sub.1-6alkyl-, SO.sub.2arylC.sub.2-6alkenyl-, SO.sub.2heteroaryl-, -heteroaryl-Q.sub.0- and -aryl-Q.sub.0-; [0102] Q.sub.0 is selected from C.sub.1-6 alkyl, -halo, CF.sub.3 and OC.sub.1-6 alkyl, [0103] R.sub.0 is H, C.sub.1-6 alkyl, -alkylsubstituted C.sub.1-6 alkyl, -alkylsubstituted(C.sub.1-6)COOR.sub.6, -spiroalkylsubstituted(C.sub.1-6)COOR.sub.6, or -arylsubstituted C.sub.1-6 alkyl; [0104] R.sub.2 is H, C.sub.1-6 alkyl, -alkylsubstituted C.sub.1-6 alkyl, or-arylsubstituted C.sub.1-6 alkyl; [0105] Y is selected from COOR.sub.2, C(O)NR.sub.2SO.sub.2R.sub.3, C(O)NHSO.sub.2NR.sub.2R.sub.2, NR.sub.2SO.sub.2R.sub.2, SO.sub.2NR.sub.2R.sub.2, C.sub.3-6 cycloalkyl-COOR.sub.2, C.sub.2-6 alkenyl-COOR.sub.2, C.sub.2-6 alkynyl-COOR.sub.2, C.sub.1-6 alkyl-COOR.sub.2, NHC(O)(CH.sub.2).sub.pCOOR.sub.2, SO.sub.2NR.sub.2C(O)R.sub.2, -tetrazole, and CONHOH, wherein p is 1-6; [0106] alternatively, Y is selected from a phenyl or heteroaryl ring, optionally further substituted with 1 to 3 substituents selected from H, -halo, -hydroxyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, COOR.sub.2, CN, NO.sub.2, CF.sub.3, SO.sub.2, NR.sub.26R.sub.27, CONR.sub.26R.sub.27, and SO.sub.2NR.sub.26R.sub.27; [0107] alternatively, X-Y is selected from

##STR00021## [0108] R.sub.3 is C.sub.1-6 alkyl or -alkylsubstituted C.sub.1-6 alkyl; [0109] Z is selected from CO and CH.sub.2; [0110] W is selected from CH.sub.2OR.sub.2, COOR.sub.2, NR.sub.4R.sub.5, CONR.sub.26R.sub.27, CH.sub.2NR.sub.26R.sub.27, NR.sub.4COR.sub.6, NR.sub.4C(O)NR.sub.4R.sub.5, and NR.sub.4COOR.sub.6; [0111] R.sub.4 is selected from H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-C(OR.sub.3).sub.2C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl, C.sub.1-6 alkyl-Q.sub.1, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl-Q.sub.1, aryl, heteroaryl, substituted heteroaryl, COR.sub.6, COCOR.sub.6, SO.sub.2R.sub.7, and SO.sub.2NR.sub.2R.sub.2, [0112] wherein Q.sub.1 is selected from C.sub.3-10 carbocycle, substituted C.sub.3-10 carbocycle, C.sub.3-10 heterocycle, substituted C.sub.3-10 hetereocycle, aryl, heteroaryl, substituted heteroaryl, halogen, CF.sub.3, OR.sub.2, COOR.sub.2, NR.sub.8R.sub.9, CONR.sub.10R.sub.11 and SO.sub.2R.sub.7; [0113] alternatively, R.sub.4 is selected from C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-heteroaryl, C.sub.1-6 alkyl-substitutedheteroaryl, C.sub.1-6 alkyl-NR.sub.6R.sub.7, C.sub.1-6 alkyl-CONR.sub.8R.sub.9, C.sub.3-6 cycloalkyl-CONR.sub.8R.sub.9, C.sub.3-6 cycloalkyl-(CH.sub.2).sub.1-3NR.sub.6R.sub.7, (CH.sub.2).sub.1-3C.sub.3-6 cycloalkyl-NR.sub.6R.sub.7; (CH.sub.2).sub.1-3C.sub.3-6 cycloalkyl-(CH.sub.2).sub.1-3NR.sub.6R.sub.7; C.sub.1-6 alkyl-Q.sub.1, C.sub.3-6 cycloalkyl-Q.sub.1, COR.sub.10, SO.sub.2R.sub.3, and

##STR00022##

wherein Q.sub.1 is selected from-hydroxy, COOR.sub.2, -halo, and SO.sub.2R.sub.a; [0114] R.sub.a is C.sub.1-6 alkyl, NR.sub.2R.sub.2,

##STR00023## [0115] R.sub.b is H, C.sub.1-6 alkyl, COR.sub.3, SO.sub.2R.sub.3, SONR.sub.3R.sub.3; [0116] R.sub.5 is selected from H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 alkylsubstituted alkyl, C.sub.1-6 alkyl-NR.sub.8R.sub.9, COR.sub.6, COCOR.sub.6, SO.sub.2R.sub.7 and SO.sub.2NR.sub.2R.sub.2; [0117] with the proviso that only one of R.sub.4 or R.sub.5 can be selected from COR.sub.6, COCOR.sub.6, SO.sub.2R.sub.7 and SO.sub.2NR.sub.2R.sub.2; [0118] R.sub.6 is selected from H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-substitutedalkyl, C.sub.3-6 cycloalkyl, C.sub.3-6 substitutedcycloalkyl-Q.sub.2, C.sub.1-6 alkyl-Q.sub.2, C.sub.1-6 alkyl-substitutedalkyl-Q.sub.2, C.sub.3-6 cycloalkyl-Q.sub.2, aryl-Q.sub.2, NR.sub.13R.sub.14, and OR.sub.15; [0119] wherein Q.sub.2 is selected from C.sub.3-10 carbocycle, substituted C.sub.3-10 carbocycle, C.sub.3-10 heterocycle, substituted C.sub.3-10 hetereocycle, aryl, heteroaryl, substituted heteroaryl, OR.sub.2, COOR.sub.2, NR.sub.8R.sub.9, SO.sub.2R.sub.7, CONHSO.sub.2R.sub.3, and CONHSO.sub.2NR.sub.2R.sub.2; [0120] R.sub.7 is selected from C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, C.sub.3-6 cycloalkyl, aryl, and heteroaryl; [0121] R.sub.8 and R.sub.9 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, C.sub.1-6 alkyl-Q.sub.2, and COOR.sub.3, [0122] alternatively R.sub.8 and R.sub.9 are taken together with the adjacent N to form a cycle selected from:

##STR00024## ##STR00025## [0123] V is selected from CR.sub.24R.sub.25, SO.sub.2, O and NR.sub.12; [0124] M is selected from CHR.sub.24R.sub.25, NR.sub.26R.sub.27, SO.sub.2R.sub.7, SO.sub.2NR.sub.3R.sub.3 and OH; [0125] with the proviso that only one of R.sub.8 or R.sub.9 can be COOR.sub.3; [0126] R.sub.10 and R.sub.11 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl and C.sub.3-6 cycloalkyl, [0127] alternatively R.sub.10 and R.sub.11 are taken together with the adjacent N to form a cycle such as

##STR00026## [0128] R.sub.12 is selected from C.sub.1-6 alkyl, C.sub.1-6 alkyl-OH; C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl,-C.sub.3-6 cycloalkyl, COR, COONR.sub.22R.sub.23, SOR.sub.7, and SONR.sub.24R.sub.25; [0129] R.sub.13 and R.sub.14 are independently selected from H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-Q.sub.3, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl-Q.sub.3 and C.sub.1-6 substituted alkyl-Q.sub.3, [0130] alternatively R.sub.13 and R.sub.14 are taken together with the adjacent N to form a cycle selected from:

##STR00027## [0131] Q.sub.3 is selected from heteroaryl, substituted heteroaryl, NR.sub.20R.sub.21, CONR.sub.2R.sub.2, COOR.sub.2, OR.sub.2, and SO.sub.2R.sub.3; [0132] R.sub.15 is selected from C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-Q.sub.3, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl-Q.sub.3 and C.sub.1-6 substituted alkyl-Q.sub.3; [0133] R.sub.16 is selected from H, C.sub.1-6 alkyl, NR.sub.2R.sub.2, and COOR.sub.3; [0134] R.sub.17 is selected from H, C.sub.1-6 alkyl, COOR.sub.3, and aryl; [0135] R.sub.18 is selected from COOR.sub.2 and C.sub.1-6 alkyl-COOR.sub.2; [0136] R.sub.19 is selected from H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-Q.sub.4, COR.sub.3, COOR.sub.3, wherein Q.sub.4 is selected from NR.sub.2R.sub.2 and OR.sub.2; [0137] R.sub.20 and R.sub.21 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 substituted alkyl-OR.sub.2, and COR.sub.3, [0138] alternatively R.sub.20 and R.sub.21 are taken together with the adjacent N to form a cycle selected from

##STR00028##

with the proviso that only one of R.sub.20 or R.sub.21 can be COR.sub.3; [0139] R.sub.22 and R.sub.23 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, and C.sub.1-6 cycloalkyl, [0140] or R.sub.22 and R.sub.23 are taken together with the adjacent N to form a cycle selected from

##STR00029## [0141] R.sub.24 and R.sub.25 are independently from the group of H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-Q.sub.5, C.sub.1-6 cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, and Q.sub.5 is selected from halogen and SO.sub.2R.sub.3, [0142] R.sub.26 and R.sub.27 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, C.sub.1-6 alkyl-Q.sub.2, and

##STR00030##

or alternatively R.sub.26 and R.sub.27 are taken together with the adjacent N to form a cycle selected from:

##STR00031##

[0143] In an aspect of the invention, there is provided a compound of Formula I, wherein R.sub.1 is isopropenyl.

[0144] In an aspect of the invention, there is provided a compound of Formula I, wherein Z is CH.sub.2.

[0145] In an aspect of the invention, there is provided a compound of Formula I, wherein n is 1.

[0146] In an aspect of the invention, there is provided a compound of Formula I, wherein n is 2.

[0147] In an aspect of the invention, there is provided a compound of Formula I, wherein X is selected from phenyl, pyridyl, pyrimidinyl, pyrazinyl, and pyradazinyl;

[0148] In an aspect of the invention, there is provided a compound of Formula I, wherein X is selected from phenyl, pyridyl, and pyrimidinyl;

[0149] In an aspect of the invention, there is provided a compound of Formula I, wherein X is phenyl.

[0150] In an aspect of the invention, there is provided a compound of Formula I, wherein Y is COOR.sub.2.

[0151] In an aspect of the invention, there is provided a compound of Formula I, wherein Y is COOH.

[0152] In an aspect of the invention, there is provided a compound of Formula I, wherein A is H.

[0153] In an aspect of the invention, there is provided a compound of Formula I, wherein X is selected from CO, COC.sub.1-6alkyl-, C.sub.1-6alkylCO, COaryl-, COheteroaryl-, SO.sub.2aryl-, and SO.sub.2heteroaryl-.

[0154] In an aspect of the invention, there is provided a compound of Formula I, wherein R.sub.4 is selected from H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-Q.sub.1, and COR.sub.6.

[0155] In an aspect of the invention, there is provided a compound of Formula I, wherein R.sub.5 is H.

[0156] In an aspect of the invention, there is provided a compound of Formula I, wherein R.sub.4 is C.sub.1-6 alkyl-Q.sub.1.

[0157] In an aspect of the invention, there is provided a compound of Formula I, wherein Q.sub.1 is NR.sub.8R.sub.9.

[0158] In an aspect of the invention, there is provided a compound of Formula I, wherein R.sub.4 is COR.sub.6.

[0159] In an aspect of the invention, there is provided a compound of Formula I, wherein W is CH.sub.2OR.sub.2

[0160] In an aspect of the invention, there is provided a compound of Formula I, wherein R.sub.2 is H.

[0161] In an aspect of the invention, there is provided a compound of Formula I, wherein W is COOR.sub.2.

[0162] In an aspect of the invention, there is provided a compound of Formula I, wherein W is COOH.

[0163] In an aspect of the invention, there is provided a compound of Formula I, wherein W is NR.sub.4R.sub.5.

[0164] In an aspect of the invention, there is provided a compound of Formula I, wherein W is CONR.sub.26R.sub.27.

[0165] In an aspect of the invention, there is provided a compound of Formula I, wherein W is CH.sub.2NR.sub.26R.sub.27.

[0166] In an aspect of the invention, there is provided a compound of Formula I, wherein W is NR.sub.4COR.sub.6.

[0167] In an aspect of the invention, there is provided a compound of Formula I, wherein W is NR.sub.4C(O)NR.sub.4R.sub.5.

[0168] In an aspect of the invention, there is provided a compound of Formula I, wherein W is NR.sub.4COOR.sub.6.

[0169] In an aspect of the invention, there is provided a compound of Formula II, including pharmaceutically acceptable salts thereof:

##STR00032##

wherein R.sub.1 is isopropenyl or isopropyl; [0170] X is a phenyl or heteroaryl ring substituted with A, wherein A is at least one member selected from H, halogen, hydroxyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.1-6 alkoxy, and COOR.sub.2; [0171] alternatively, X is selected from a single bond, C.sub.1-6alkyl-, C.sub.1-6alkylaryl-, C.sub.2-6alkenyl-, C.sub.2-6alkenylaryl-, CO, SO.sub.2, C.sub.1-6alkylCO, C.sub.2-6alkenylCO, COalkylsubstituted C.sub.1-6 alkyl-, COspiroalkylsubstitutedC.sub.1-6 alkyl-, COarylsubstitutedC.sub.1-6 alkyl-, COarylsubstituted C.sub.2-6 alkenyl-, COheteroaryl-, COaryl-, COC.sub.1-6 alkylaryl-, COC.sub.1-6 alkylheteroaryl-, COalkylsubstituted C.sub.3-6 cycloalkyl-, COC.sub.2-6 alkenylaryl-, COC.sub.1-6 alkyl(NHR.sub.0), C.sub.1-6 alkyl(CONHR.sub.0), (COCO)NR.sub.0SO.sub.2, SO.sub.2C.sub.1-6 alkyl-, SO.sub.2alkylsubstitutedC.sub.1-6 alkyl-, SO.sub.2arylsubstituted C.sub.1-6 alkyl-, SO.sub.2C.sub.1-6 alkylaryl-, SO.sub.2C.sub.2-6 alkenylaryl-, SO.sub.2aryl-, SO.sub.2arylC.sub.1-6alkyl-, SO.sub.2arylC.sub.2-6alkenyl-, SO.sub.2heteroaryl-, -heteroaryl-Q.sub.0- and -aryl-Q.sub.0-; [0172] Q.sub.0 is selected from C.sub.1-6 alkyl, -halo, CF.sub.3 and OC.sub.1-6 alkyl, [0173] R.sub.0 is H, C.sub.1-6 alkyl, -alkylsubstituted C.sub.1-6 alkyl, -alkylsubstituted(C.sub.1-6)COOR.sub.6, -spiroalkylsubstituted(C.sub.1-6)COOR.sub.6, or -arylsubstituted C.sub.1-6 alkyl; [0174] R.sub.2 is H, C.sub.1-6 alkyl, -alkylsubstituted C.sub.1-6 alkyl, or-arylsubstituted C.sub.1-6 alkyl; [0175] Y is selected from COOR.sub.2, C(O)NR.sub.2SO.sub.2R.sub.3, C(O)NHSO.sub.2NR.sub.2R.sub.2, NR.sub.2SO.sub.2R.sub.2, SO.sub.2NR.sub.2R.sub.2, C.sub.3-6 cycloalkyl-COOR.sub.2, C.sub.2-6 alkenyl-COOR.sub.2, C.sub.2-6 alkynyl-COOR.sub.2, C.sub.1-6 alkyl-COOR.sub.2, NHC(O)(CH.sub.2).sub.pCOOR.sub.2, SO.sub.2NR.sub.2C(O)R.sub.2, -tetrazole, and CONHOH, wherein p is 1-6; [0176] alternatively, Y is selected from a phenyl or heteroaryl ring, optionally further substituted with 1 to 3 substituents selected from H, -halo, -hydroxyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, COOR.sub.2, CN, NO.sub.2, CF.sub.3, SO.sub.2, NR.sub.26R.sub.27, CONR.sub.26R.sub.27, and SO.sub.2NR.sub.26R.sub.27; [0177] alternatively, X-Y is selected from

##STR00033## [0178] R.sub.3 is C.sub.1-6 alkyl or -alkylsubstituted C.sub.1-6 alkyl; [0179] Z is selected from CO and CH.sub.2; [0180] W is selected from CH.sub.2OR.sub.2, COOR.sub.2, NR.sub.4R.sub.5, CONR.sub.26R.sub.27, CH.sub.2NR.sub.26R.sub.27, NR.sub.4COR.sub.6, NR.sub.4C(O)NR.sub.4R.sub.5, and NR.sub.4COOR.sub.6; [0181] R.sub.4 is selected from H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-C(OR.sub.3).sub.2C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl, C.sub.1-6 alkyl-Q.sub.1, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl-Q.sub.1, aryl, heteroaryl, substituted heteroaryl, COR.sub.6, COCOR.sub.6, SO.sub.2R.sub.7, and SO.sub.2NR.sub.2R.sub.2, [0182] wherein Q.sub.1 is selected from C.sub.3-10 carbocycle, substituted C.sub.3-10 carbocycle, C.sub.3-10 heterocycle, substituted C.sub.3-10 hetereocycle, aryl, heteroaryl, substituted heteroaryl, halogen, CF.sub.3, OR.sub.2, COOR.sub.2, NR.sub.8R.sub.9, CONR.sub.10R.sub.11 and SO.sub.2R.sub.7; [0183] alternatively, R.sub.4 is selected from C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-heteroaryl, C.sub.1-6 alkyl-substitutedheteroaryl, C.sub.1-6 alkyl-NR.sub.6R.sub.7, C.sub.1-6 alkyl-CONR.sub.8R.sub.9, C.sub.3-6 cycloalkyl-CONR.sub.8R.sub.9, C.sub.3-6 cycloalkyl-(CH.sub.2) i-3-NR.sub.6R.sub.7, (CH.sub.2).sub.1-3C.sub.3-6 cycloalkyl-NR.sub.6R.sub.7; (CH.sub.2).sub.1-3C.sub.3-6 cycloalkyl-(CH.sub.2).sub.1-3NR.sub.6R.sub.7; C.sub.1-6 alkyl-Q.sub.1, C.sub.3-6 cycloalkyl-Q.sub.1, COR.sub.10, SO.sub.2R.sub.3, and

##STR00034##

wherein Q.sub.1 is selected from-hydroxy, COOR.sub.2, -halo, and SO.sub.2R.sub.a; [0184] R.sub.a is C.sub.1-6 alkyl, NR.sub.2R.sub.2,

##STR00035## [0185] R.sub.b is H, C.sub.1-6 alkyl, COR.sub.3, SO.sub.2R.sub.3, SONR.sub.3R.sub.3; [0186] R.sub.5 is selected from H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 alkylsubstituted alkyl, C.sub.1-6 alkyl-NR.sub.8R.sub.9, COR.sub.6, COCOR.sub.6, SO.sub.2R.sub.7 and SO.sub.2NR.sub.2R.sub.2; [0187] with the proviso that only one of R.sub.4 or R.sub.5 can be selected from COR.sub.6, COCOR.sub.6, SO.sub.2R.sub.7 and SO.sub.2NR.sub.2R.sub.2; [0188] R.sub.6 is selected from H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-substitutedalkyl, C.sub.3-6 cycloalkyl, C.sub.3-6 substitutedcycloalkyl-Q.sub.2, C.sub.1-6alkyl-Q.sub.2, C.sub.1-6 alkyl-substitutedalkyl-Q.sub.2, C.sub.3-6 cycloalkyl-Q.sub.2, aryl-Q.sub.2, NR.sub.13R.sub.14, and OR.sub.15; [0189] wherein Q.sub.2 is selected from C.sub.3-10 carbocycle, substituted C.sub.3-10 carbocycle, C.sub.3-10 heterocycle, substituted C.sub.3-10 hetereocycle, aryl, heteroaryl, substituted heteroaryl, OR.sub.2, COOR.sub.2, NR.sub.8R.sub.9, SO.sub.2R.sub.7, CONHSO.sub.2R.sub.3, and CONHSO.sub.2NR.sub.2R.sub.2; [0190] R.sub.7 is selected from C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, C.sub.3-6 cycloalkyl, aryl, and heteroaryl; [0191] R.sub.8 and R.sub.9 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, C.sub.1-6alkyl-Q.sub.2, and COOR.sub.3, [0192] alternatively R.sub.8 and R.sub.9 are taken together with the adjacent N to form a cycle selected from:

##STR00036## ##STR00037## [0193] V is selected from CR.sub.24R.sub.25, O and NR.sub.12; [0194] M is selected from CHR.sub.24R.sub.25, NR.sub.26R.sub.27, SO.sub.2R.sub.7, SO.sub.2NR.sub.3R.sub.3 and OH; [0195] with the proviso that only one of R.sub.8 or R.sub.9 can be COOR.sub.3; [0196] R.sub.10 and R.sub.11 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl and C.sub.3-6 cycloalkyl, [0197] alternatively R.sub.10 and R.sub.11 are taken together with the adjacent N to form a cycle such as

##STR00038## [0198] R.sub.12 is selected from C.sub.1-6 alkyl, C.sub.1-6 alkyl-OH; C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl,-C.sub.3-6 cycloalkyl, COR, COONR.sub.22R.sub.23, SOR.sub.7, and SONR.sub.24R.sub.25; [0199] R.sub.13 and R.sub.14 are independently selected from H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-Q.sub.3, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl-Q.sub.3 and C.sub.1-6 substituted alkyl-Q.sub.3, [0200] alternatively R.sub.13 and R.sub.14 are taken together with the adjacent N to form a cycle selected from:

##STR00039## [0201] Q.sub.3 is selected from heteroaryl, substituted heteroaryl, NR.sub.20R.sub.21, CONR.sub.2R.sub.2, COOR.sub.2, OR.sub.2, and SO.sub.2R.sub.3; [0202] R.sub.15 is selected from C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-Q.sub.3, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl-Q.sub.3 and C.sub.1-6 substituted alkyl-Q.sub.3; [0203] R.sub.16 is selected from H, C.sub.1-6 alkyl, NR.sub.2R.sub.2, and COOR.sub.3; [0204] R.sub.17 is selected from H, C.sub.1-6 alkyl, COOR.sub.3, and aryl; [0205] R.sub.18 is selected from COOR.sub.2 and C.sub.1-6 alkyl-COOR.sub.2; [0206] R.sub.19 is selected from H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-Q.sub.4, COR.sub.3, COOR.sub.3, wherein Q.sub.4 is selected from NR.sub.2R.sub.2 and OR.sub.2; [0207] R.sub.20 and R.sub.21 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 substituted alkyl-OR.sub.2, and COR.sub.3, [0208] alternatively R.sub.20 and R.sub.21 are taken together with the adjacent N to form a cycle selected from

##STR00040##

with the proviso that only one of R.sub.20 or R.sub.21 can be COR.sub.3, [0209] R.sub.22 and R.sub.23 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, and C.sub.1-6 cycloalkyl, [0210] or R.sub.22 and R.sub.23 are taken together with the adjacent N to form a cycle selected from

##STR00041## [0211] R.sub.24 and R.sub.25 are independently from the group of H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-Q.sub.5, C.sub.1-6 cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, and Q.sub.5 is selected from halogen and SO.sub.2R.sub.3, [0212] R.sub.26 and R.sub.27 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, C.sub.1-6 alkyl-Q.sub.2, and

##STR00042##

or alternatively R.sub.26 and R.sub.27 are taken together with the adjacent N to form a cycle selected from:

##STR00043##

[0213] In an aspect of the invention, there is provided a compound of Formula IIII, including pharmaceutically acceptable salts thereof:

##STR00044##

wherein R.sub.1 is isopropenyl or isopropyl; [0214] X is a phenyl or heteroaryl ring substituted with A, wherein A is at least one member selected from H, halogen, hydroxyl, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.1-6 alkoxy, and COOR.sub.2; [0215] alternatively, X is selected from a single bond, C.sub.1-6alkyl-, C.sub.1-6alkylaryl-, C.sub.2-6alkenyl-, C.sub.2-6alkenylaryl-, CO, SO.sub.2, C.sub.1-6alkylCO, C.sub.2-6alkenylCO, COalkylsubstituted C.sub.1-6 alkyl-, COspiroalkylsubstitutedC.sub.1-6 alkyl-, COarylsubstitutedC.sub.1-6 alkyl-, COarylsubstituted C.sub.2-6 alkenyl-, COheteroaryl-, COaryl-, COC.sub.1-6 alkylaryl-, COC.sub.1-6 alkylheteroaryl-, COalkylsubstituted C.sub.3-6 cycloalkyl-, COC.sub.2-6 alkenylaryl-, COC.sub.1-6 alkyl(NHR.sub.0), C.sub.1-6 alkyl(CONHR.sub.0), (COCO)NR.sub.0SO.sub.2, SO.sub.2C.sub.1-6 alkyl-, SO.sub.2alkylsubstitutedC.sub.1-6 alkyl-, SO.sub.2arylsubstituted C.sub.1-6 alkyl-, SO.sub.2C.sub.1-6 alkylaryl-, SO.sub.2C.sub.2-6 alkenylaryl-, SO.sub.2aryl-, SO.sub.2arylC.sub.1-6alkyl-, SO.sub.2arylC.sub.2-6alkenyl-, SO.sub.2heteroaryl-, -heteroaryl-Q.sub.0- and -aryl-Q.sub.0-; [0216] Q.sub.0 is selected from C.sub.1-6 alkyl, -halo, CF.sub.3 and OC.sub.1-6 alkyl, [0217] R.sub.0 is H, C.sub.1-6 alkyl, -alkylsubstituted C.sub.1-6 alkyl, -alkylsubstituted(C.sub.1-6)COOR.sub.6, -spiroalkylsubstituted(C.sub.1-6)COOR.sub.6, or -arylsubstituted C.sub.1-6 alkyl; [0218] R.sub.2 is H, C.sub.1-6 alkyl, -alkylsubstituted C.sub.1-6 alkyl, or-arylsubstituted C.sub.1-6 alkyl; [0219] Y is selected from COOR.sub.2, C(O)NR.sub.2SO.sub.2R.sub.3, C(O)NHSO.sub.2NR.sub.2R.sub.2, NR.sub.2SO.sub.2R.sub.2, SO.sub.2NR.sub.2R.sub.2, C.sub.3-6 cycloalkyl-COOR.sub.2, C.sub.2-6 alkenyl-COOR.sub.2, C.sub.2-6 alkynyl-COOR.sub.2, C.sub.1-6 alkyl-COOR.sub.2, NHC(O)(CH.sub.2).sub.pCOOR.sub.2, SO.sub.2NR.sub.2C(O)R.sub.2, -tetrazole, and CONHOH, wherein p is 1-6; [0220] alternatively, Y is selected from a phenyl or heteroaryl ring, optionally further substituted with 1 to 3 substituents selected from H, -halo, -hydroxyl, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, COOR.sub.2, CN, NO.sub.2, CF.sub.3, SO.sub.2, NR.sub.26R.sub.27, CONR.sub.26R.sub.27, and SO.sub.2NR.sub.26R.sub.27; [0221] alternatively, X-Y is selected from

##STR00045## [0222] R.sub.3 is C.sub.1-6 alkyl or -alkylsubstituted C.sub.1-6 alkyl; [0223] Z is selected from CO and CH.sub.2; [0224] W is selected from CH.sub.2OR.sub.2, COOR.sub.2, NR.sub.4R.sub.5, CONR.sub.26R.sub.27, CH.sub.2NR.sub.26R.sub.27, NR.sub.4COR.sub.6, NR.sub.4C(O)NR.sub.4R.sub.5, and NR.sub.4COOR.sub.6; [0225] R.sub.4 is selected from H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-C(OR.sub.3).sub.2C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl, C.sub.1-6 alkyl-Q.sub.1, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl-Q.sub.1, aryl, heteroaryl, substituted heteroaryl, COR.sub.6, COCOR.sub.6, SO.sub.2R.sub.7, and SO.sub.2NR.sub.2R.sub.2, [0226] wherein Q.sub.1 is selected from C.sub.3-10 carbocycle, substituted C.sub.3-10 carbocycle, C.sub.3-10 heterocycle, substituted C.sub.3-10 hetereocycle, aryl, heteroaryl, substituted heteroaryl, halogen, CF.sub.3, OR.sub.2, COOR.sub.2, NR.sub.8R.sub.9, CONR.sub.10R.sub.11 and SO.sub.2R.sub.7; [0227] alternatively, R.sub.4 is selected from C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-heteroaryl, C.sub.1-6 alkyl-substitutedheteroaryl, C.sub.1-6 alkyl-NR.sub.6R.sub.7, C.sub.1-6 alkyl-CONR.sub.8R.sub.9, C.sub.3-6 cycloalkyl-CONR.sub.8R.sub.9, C.sub.3-6 cycloalkyl-(CH.sub.2) i-3-NR.sub.6R.sub.7, (CH.sub.2).sub.1-3C.sub.3-6 cycloalkyl-NR.sub.6R.sub.7; (CH.sub.2).sub.1-3C.sub.3-6 cycloalkyl-(CH.sub.2).sub.1-3NR.sub.6R.sub.7; C.sub.1-6 alkyl-Q.sub.1, C.sub.3-6 cycloalkyl-Q.sub.1, COR.sub.10, SO.sub.2R.sub.3, and

##STR00046##

wherein Q.sub.1 is selected from-hydroxy, COOR.sub.2, -halo, and SO.sub.2R.sub.a; [0228] R.sub.a is C.sub.1-6 alkyl, NR.sub.2R.sub.2,

##STR00047## [0229] R.sub.b is H, C.sub.1-6 alkyl, COR.sub.3, SO.sub.2R.sub.3, SONR.sub.3R.sub.3; [0230] R.sub.5 is selected from H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 alkylsubstituted alkyl, C.sub.1-6 alkyl-NR.sub.8R.sub.9, COR.sub.6, COCOR.sub.6, SO.sub.2R.sub.7 and SO.sub.2NR.sub.2R.sub.2; [0231] with the proviso that only one of R.sub.4 or R.sub.5 can be selected from COR.sub.6, COCOR.sub.6, SO.sub.2R.sub.7 and SO.sub.2NR.sub.2R.sub.2; [0232] R.sub.6 is selected from H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-substitutedalkyl, C.sub.3-6 cycloalkyl, C.sub.3-6 substitutedcycloalkyl-Q.sub.2, C.sub.1-6 alkyl-Q.sub.2, C.sub.1-6 alkyl-substitutedalkyl-Q.sub.2, C.sub.3-6 cycloalkyl-Q.sub.2, aryl-Q.sub.2, NR.sub.13R.sub.14, and OR.sub.15; [0233] wherein Q.sub.2 is selected from C.sub.3-10 carbocycle, substituted C.sub.3-10 carbocycle, C.sub.3-10 heterocycle, substituted C.sub.3-10 hetereocycle, aryl, heteroaryl, substituted heteroaryl, OR.sub.2, COOR.sub.2, NR.sub.8R.sub.9, SO.sub.2R.sub.7, CONHSO.sub.2R.sub.3, and CONHSO.sub.2NR.sub.2R.sub.2; [0234] R.sub.7 is selected from C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, C.sub.3-6 cycloalkyl, aryl, and heteroaryl; [0235] R.sub.8 and R.sub.9 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, C.sub.1-6 alkyl-Q.sub.2, and COOR.sub.3, [0236] alternatively R.sub.8 and R.sub.9 are taken together with the adjacent N to form a cycle selected from:

##STR00048## ##STR00049## [0237] V is selected from CR.sub.24R.sub.25, O and NR.sub.12; [0238] M is selected from CHR.sub.24R.sub.25, NR.sub.26R.sub.27, SO.sub.2R.sub.7, SO.sub.2NR.sub.3R.sub.3 and OH; [0239] with the proviso that only one of R.sub.8 or R.sub.9 can be COOR.sub.3; [0240] R.sub.10 and R.sub.11 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl and C.sub.3-6 cycloalkyl, [0241] alternatively R.sub.10 and R.sub.11 are taken together with the adjacent N to form a cycle such as

##STR00050## [0242] R.sub.12 is selected from C.sub.1-6 alkyl, C.sub.1-6 alkyl-OH; C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl,-C.sub.3-6 cycloalkyl, COR, COONR.sub.22R.sub.23, SOR.sub.7, and SONR.sub.24R.sub.25; [0243] R.sub.13 and R.sub.14 are independently selected from H, C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-Q.sub.3, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl-Q.sub.3 and C.sub.1-6 substituted alkyl-Q.sub.3, [0244] alternatively R.sub.13 and R.sub.14 are taken together with the adjacent N to form a cycle selected from:

##STR00051## [0245] Q.sub.3 is selected from heteroaryl, substituted heteroaryl, NR.sub.20R.sub.21, CONR.sub.2R.sub.2, COOR.sub.2, OR.sub.2, and SO.sub.2R.sub.3; [0246] R.sub.15 is selected from C.sub.1-6 alkyl, C.sub.3-6 cycloalkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-Q.sub.3, C.sub.1-6 alkyl-C.sub.3-6 cycloalkyl-Q.sub.3 and C.sub.1-6 substituted alkyl-Q.sub.3;

[0247] R.sub.16 is selected from H, C.sub.1-6 alkyl, NR.sub.2R.sub.2, and COOR.sub.3; [0248] R.sub.17 is selected from H, C.sub.1-6 alkyl, COOR.sub.3, and aryl; [0249] R.sub.18 is selected from COOR.sub.2 and C.sub.1-6 alkyl-COOR.sub.2; [0250] R.sub.19 is selected from H, C.sub.1-6 alkyl, C.sub.1-6 alkyl-Q.sub.4, COR.sub.3, COOR.sub.3, wherein Q.sub.4 is selected from NR.sub.2R.sub.2 and OR.sub.2; [0251] R.sub.20 and R.sub.21 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 substituted alkyl-OR.sub.2, and COR.sub.3, [0252] alternatively R.sub.20 and R.sub.21 are taken together with the adjacent N to form a cycle selected from

##STR00052##

with the proviso that only one of R.sub.20 or R.sub.21 can be COR.sub.3, [0253] R.sub.22 and R.sub.23 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, and C.sub.1-6 cycloalkyl, [0254] or R.sub.22 and R.sub.23 are taken together with the adjacent N to form a cycle selected from

##STR00053## [0255] R.sub.24 and R.sub.25 are independently from the group of H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, C.sub.1-6 alkyl-Q.sub.5, C.sub.1-6 cycloalkyl, aryl, substituted aryl, heteroaryl, and substituted heteroaryl, and Q.sub.5 is selected from halogen and SO.sub.2R.sub.3, [0256] R.sub.26 and R.sub.27 are independently selected from H, C.sub.1-6 alkyl, C.sub.1-6 substituted alkyl, aryl, heteroaryl, substituted aryl, substituted heteroaryl, C.sub.1-6 alkyl-Q.sub.2, and

##STR00054##

or alternatively R.sub.26 and R.sub.27 are taken together with the adjacent N to form a cycle selected from:

##STR00055##

[0257] In an aspect of the invention, there is provided a compound, including pharmaceutically acceptable salts thereof, which is selected from:

##STR00056## ##STR00057## ##STR00058## ##STR00059## ##STR00060## ##STR00061## ##STR00062## ##STR00063## ##STR00064## ##STR00065## ##STR00066##

[0258] In an aspect of the invention, there is provided a composition useful for treating HIV infection comprising a therapeutic amount of a compound of Formula I, II or III and a pharmaceutically acceptable carrier. In an aspect of the invention, the composition further comprises a therapeutically effective amount at least one other agent used for treatment of AIDS or HIV infection selected from nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors, and a pharmaceutically acceptable carrier. In an aspect of the invention, the other agent is dolutegravir.

[0259] In an aspect of the invention, there is provided a method for treating HIV infection comprising administering a therapeutically effective amount of a compound of Formula I, II or III or a pharmaceutically acceptable salt thereof, to a patient in need thereof. In an aspect of the invention, the method further comprises administering a therapeutically effective amount of at least one other agent used for treatment of AIDS or HIV infection selected from nucleoside HIV reverse transcriptase inhibitors, non-nucleoside HIV reverse transcriptase inhibitors, HIV protease inhibitors, HIV fusion inhibitors, HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV budding or maturation inhibitors, and HIV integrase inhibitors. In an aspect of the invention, the other agent is dolutegravir. In an aspect of the invention, the other agent is administered to the patient prior to, simultaneously with, or subsequently to the compound of Formula I, II or III.

Pharmaceutical Compositions and Methods of Use

[0260] The compounds of the invention herein described and set forth are generally given as pharmaceutical compositions. These compositions are comprised of a therapeutically effective amount of a compound of Formula I or its pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier and may contain conventional excipients and/or diluents. A therapeutically effective amount is that which is needed to provide a meaningful patient benefit. Pharmaceutically acceptable carriers are those conventionally known carriers having acceptable safety profiles. Compositions encompass all common solid and liquid forms, including capsules, tablets, lozenges, and powders, as well as liquid suspensions, syrups, elixirs, and solutions. Compositions are made using available formulation techniques, and excipients (such as binding and wetting agents) and vehicles (such as water and alcohols) which are generally used for compositions. See, for example, Remington's Pharmaceutical Sciences, 17th edition, Mack Publishing Company, Easton, Pa. (1985).

[0261] Solid compositions which are normally formulated in dosage units and compositions providing from about 1 to 1000 mg of the active ingredient per dose are preferred. Some examples of dosages are 1 mg, 10 mg, 100 mg, 250 mg, 500 mg, and 1000 mg. Generally, other antiretroviral agents will be present in a unit range similar to agents of that class used clinically. Typically, this is about 0.25-1000 mg/unit.

[0262] Liquid compositions are usually in dosage unit ranges. Generally, the liquid composition will be in a unit dosage range of about 1-100 mg/mL. Some examples of dosages are 1 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/mL. Generally, other antiretroviral agents will be present in a unit range similar to agents of that class used clinically. Typically, this is about 1-100 mg/mL.

[0263] The invention encompasses all conventional modes of administration; oral and parenteral methods are preferred. Generally, the dosing regimen will be similar to other antiretroviral agents used clinically. Typically, the daily dose will be about 1-100 mg/kg body weight daily. Generally, more compound is required orally and less parenterally. The specific dosing regimen, however, will be determined by a physician using sound medical judgment.

[0264] The compounds of this invention desirably have activity against HIV. Accordingly, another aspect of the invention is a method for treating HIV infection in a human patient comprising administering a therapeutically effective amount of a compound of Formula I, including a pharmaceutically acceptable salt thereof, with a pharmaceutically acceptable carrier, excipient and/or diluent.

[0265] The invention also encompasses methods where the compound is given in combination therapy. That is, the compound can be used in conjunction with, but separately from, other agents useful in treating AIDS and HIV infection. The compound can also be used in combination therapy wherein the compound and one or more of the other agents are physically together in a fixed-dose combination (FDC). Some of these agents include HIV attachment inhibitors, CCR5 inhibitors, CXCR4 inhibitors, HIV cell fusion inhibitors, HIV integrase inhibitors, HIV nucleoside reverse transcriptase inhibitors, HIV non-nucleoside reverse transcriptase inhibitors, HIV protease inhibitors, budding and maturation inhibitors, immunomodulators, and anti-infectives. In these combination methods, the compound of Formula I will generally be given in a daily dose of about 1-100 mg/kg body weight daily in conjunction with other agents. The other agents generally will be given in the amounts used therapeutically. The specific dosing regimen, however, will be determined by a physician using sound medical judgment.

[0266] Combination, coadministration, concurrent and similar terms referring to the administration of a compound of Formula I with at least one anti-HIV agent mean that the components are part of a combination antiretroviral therapy or HAART as understood by practitioners in the field of AIDS and HIV infection.

[0267] Thus, as set forth above, contemplated herein are combinations of the compounds of Formula I, together with one or more agents useful in the treatment of AIDS. For example, the compounds of the invention may be effectively administered, whether at periods of pre-exposure and/or post-exposure, in combination with effective amounts of the AIDS antivirals, immunomodulators, anti-infectives, or vaccines, such as those in the following non-limiting table:

TABLE-US-00001 ANTIVIRALS Drug Name Manufacturer Indication Rilpivirine Tibotec HIV infection, AIDS, ARC (non-nucleoside reverse transcriptase inhibitor) COMPLERA Gilead HIV infection, AIDS, ARC; combination with emtricitabine, rilpivirine, and tenofovir disoproxil fumarate 097 Hoechst/Bayer HIV infection, AIDS, ARC (non-nucleoside reverse trans- criptase (RT) inhibitor) Amprenavir Glaxo Wellcome HIV infection, 141 W94 AIDS, ARC GW 141 (protease inhibitor) Abacavir (1592U89) Glaxo Wellcome HIV infection, GW 1592 AIDS, ARC (RT inhibitor) Acemannan Carrington Labs ARC (Irving, TX) Acyclovir Burroughs Wellcome HIV infection, AIDS, ARC AD-439 Tanox Biosystems HIV infection, AIDS, ARC AD-519 Tanox Biosystems HIV infection, AIDS, ARC Adefovir dipivoxil Gilead Sciences HIV infection AL-721 Ethigen ARC, PGL (Los Angeles, CA) HIV positive, AIDS Alpha Interferon Glaxo Wellcome Kaposi's sarcoma, HIV in combination w/Retrovir Ansamycin Adria Laboratories ARC LM 427 (Dublin, OH) Erbamont (Stamford, CT) Antibody which Advanced Biotherapy AIDS, ARC Neutralizes pH Concepts Labile alpha aberrant (Rockville, MD) Interferon AR177 Aronex Pharm HIV infection, AIDS, ARC Beta-fluoro-ddA Nat'l Cancer Institute AIDS-associated diseases CI-1012 Warner-Lambert HIV-1 infection Cidofovir Gilead Science CMV retinitis, herpes, papillomavirus Curdlan sulfate AJI Pharma USA HIV infection Cytomegalovirus MedImmune CMV retinitis Immune globin Cytovene Syntex Sight threatening Ganciclovir CMV peripheral CMV retinitis Darunavir Tibotec-J & J HIV infection, AIDS, ARC (protease inhibitor) Delaviridine Pharmacia-Upjohn HIV infection, AIDS, ARC (RT inhibitor) Dextran Sulfate Ueno Fine Chem. AIDS, ARC, HIV Ind. Ltd. (Osaka, positive Japan) asymptomatic ddC Hoffman-La Roche HIV infection, AIDS, Dideoxycytidine ARC ddI Bristol-Myers Squibb HIV infection, AIDS, Dideoxyinosine ARC; combination with AZT/d4T DMP-450 AVID HIV infection, (Camden, NJ) AIDS, ARC (protease inhibitor) Efavirenz Bristol Myers Squibb HIV infection, (DMP 266, SUSTIVA) AIDS, ARC ()6-Chloro-4-(S)- (non-nucleoside RT cyclopropylethynyl- inhibitor) 4(S)-trifluoro- methyl-1,4-dihydro- 2H-3,1-benzoxazin- 2-one, STOCRINE EL10 Elan Corp, PLC HIV infection (Gainesville, GA) Etravirine Tibotec/J & J HIV infection, AIDS, ARC (non-nucleoside reverse transcriptase inhibitor) Famciclovir Smith Kline herpes zoster, herpes simplex GS 840 Gilead HIV infection, AIDS, ARC (reverse transcriptase inhibitor) HBY097 Hoechst Marion HIV infection, Roussel AIDS, ARC (non-nucleoside reverse transcriptase inhibitor) Hypericin VIMRx Pharm. HIV infection, AIDS, ARC Recombinant Human Triton Biosciences AIDS, Kaposi's Interferon Beta (Almeda, CA) sarcoma, ARC Interferon alfa-n3 Interferon Sciences ARC, AIDS Indinavir Merck HIV infection, AIDS, ARC, asymptomatic HIV positive, also in combination with AZT/ddI/ddC ISIS 2922 ISIS Pharmaceuticals CMV retinitis KNI-272 Nat'l Cancer Institute HIV-assoc. diseases Lamivudine, 3TC Glaxo Wellcome HIV infection, AIDS, ARC (reverse transcriptase inhibitor); also with AZT Lobucavir Bristol-Myers Squibb CMV infection Nelfinavir Agouron HIV infection, Pharmaceuticals AIDS, ARC (protease inhibitor) Nevirapine Boeheringer HIV infection, Ingleheim AIDS, ARC (RT inhibitor) Novapren Novaferon Labs, Inc. HIV inhibitor (Akron, OH) Peptide T Peninsula Labs AIDS Octapeptide (Belmont, CA) Sequence Trisodium Astra Pharm. CMV retinitis, HIV Phosphonoformate Products, Inc. infection, other CMV infections PNU-140690 Pharmacia Upjohn HIV infection, AIDS, ARC (protease inhibitor) Probucol Vyrex HIV infection, AIDS RBC-CD4 Sheffield Med. HIV infection, Tech (Houston, TX) AIDS, ARC Ritonavir Abbott HIV infection, AIDS, ARC (protease inhibitor) Saquinavir Hoffmann- HIV infection, LaRoche AIDS, ARC (protease inhibitor) Stavudine; d4T Bristol-Myers Squibb HIV infection, AIDS, Didehydrodeoxy- ARC Thymidine Tipranavir Boehringer Ingelheim HIV infection, AIDS, ARC (protease inhibitor) Valaciclovir Glaxo Wellcome Genital HSV & CMV Infections Virazole Viratek/ICN asymptomatic HIV Ribavirin (Costa Mesa, CA) positive, LAS, ARC VX-478 Vertex HIV infection, AIDS, ARC Zalcitabine Hoffmann-LaRoche HIV infection, AIDS, ARC, with AZT Zidovudine; AZT Glaxo Wellcome HIV infection, AIDS, ARC, Kaposi's sarcoma, in combination with other therapies Tenofovir disoproxil, Gilead HIV infection, fumarate salt (VIREAD) AIDS, (reverse transcriptase inhibitor) EMTRIVA Gilead HIV infection, (Emtricitabine) (FTC) AIDS, (reverse transcriptase inhibitor) COMBIVIR GSK HIV infection, AIDS, (reverse transcriptase inhibitor) Abacavir succinate GSK HIV infection, (or ZIAGEN) AIDS, (reverse transcriptase inhibitor) REYATAZ Bristol-Myers Squibb HIV infection (or atazanavir) AIDs, protease inhibitor FUZEON Roche/Trimeris HIV infection (Enfuvirtide or T-20) AIDs, viral Fusion inhibitor LEXIVA GSK/Vertex HIV infection (or Fosamprenavir calcium) AIDs, viral protease inhibitor SELZENTRY Pfizer HIV infection Maraviroc; (UK 427857) AIDs, (CCR5 antagonist, in development) TRIZIVIR GSK HIV infection AIDs, (three drug combination) Sch-417690 (vicriviroc) Schering-Plough HIV infection AIDs, (CCR5 antagonist, in development) TAK-652 Takeda HIV infection AIDs, (CCR5 antagonist, in development) GSK 873140 GSK/ONO HIV infection (ONO-4128) AIDs, (CCR5 antagonist, in development) Integrase Inhibitor Merck HIV infection MK-0518 AIDs Raltegravir TRUVADA Gilead Combination of Tenofovir disoproxil fumarate salt (VIREAD) and EMTRIVA (Emtricitabine) Integrase Inhibitor Gilead/Japan Tobacco HIV Infection GS917/JTK-303 AIDs Elvitegravir in development Triple drug combination Gilead/Bristol-Myers Squibb Combination of Tenofovir ATRIPLA disoproxil fumarate salt (VIREAD), EMTRIVA (Emtricitabine), and SUSTIVA (Efavirenz) FESTINAVIR Oncolys BioPharma HIV infection AIDs in development CMX-157 Chimerix HIV infection Lipid conjugate of AIDs nucleotide tenofovir G5K1349572 GSK HIV infection Integrase inhibitor AIDs TIVICAY dolutegravir IMMUNOMODULATORS Drug Name Manufacturer Indication AS-101 Wyeth-Ayerst AIDS Bropirimine Pharmacia Upjohn Advanced AIDS Acemannan Carrington Labs, Inc. AIDS, ARC (Irving, TX) CL246, 738 Wyeth AIDS, Kaposi's Lederle Labs sarcoma FP-21399 Fuki ImmunoPharm Blocks HIV fusion with CD4+ cells Gamma Interferon Genentech ARC, in combination w/TNF (tumor necrosis factor) Granulocyte Genetics Institute AIDS Macrophage Colony Sandoz Stimulating Factor Granulocyte Hoechst-Roussel AIDS Macrophage Colony Immunex Stimulating Factor Granulocyte Schering-Plough AIDS, Macrophage Colony combination Stimulating Factor w/AZT HIV Core Particle Rorer Seropositive HIV Immunostimulant IL-2 Cetus AIDS, in combination Interleukin-2 w/AZT IL-2 Hoffman-LaRoche AIDS, ARC, HIV, in Interleukin-2 Immunex combination w/AZT IL-2 Chiron AIDS, increase in Interleukin-2 CD4 cell counts (aldeslukin) Immune Globulin Cutter Biological Pediatric AIDS, in Intravenous (Berkeley, CA) combination w/AZT (human) IMREG-1 Imreg AIDS, Kaposi's (New Orleans, LA) sarcoma, ARC, PGL IMREG-2 Imreg AIDS, Kaposi's (New Orleans, LA) sarcoma, ARC, PGL Imuthiol Diethyl Merieux Institute AIDS, ARC Dithio Carbamate Alpha-2 Schering Plough Kaposi's sarcoma Interferon w/AZT, AIDS Methionine- TNI Pharmaceutical AIDS, ARC Enkephalin (Chicago, IL) MTP-PE Ciba-Geigy Corp. Kaposi's sarcoma Muramyl-Tripeptide Granulocyte Amgen AIDS, in combination Colony Stimulating w/AZT Factor Remune Immune Response Immunotherapeutic Corp. rCD4 Genentech AIDS, ARC Recombinant Soluble Human CD4 rCD4-IgG AIDS, ARC hybrids Recombinant Biogen AIDS, ARC Soluble Human CD4 Interferon Hoffman-La Roche Kaposi's sarcoma Alfa 2a AIDS, ARC, in combination w/AZT SK & F 106528 Smith Kline HIV infection Soluble T4 Thymopentin Immunobiology HIV infection Research Institute (Annandale, NJ) Tumor Necrosis Genentech ARC, in combination Factor; TNF w/gamma Interferon ANTI-INFECTIVES Drug Name Manufacturer Indication Clindamycin with Pharmacia Upjohn PCP Primaquine Fluconazole Pfizer Cryptococcal meningitis, candidiasis Pastille Squibb Corp. Prevention of Nystatin Pastille oral candidiasis Ornidyl Merrell Dow PCP Eflornithine Pentamidine LyphoMed PCP treatment Isethionate (IM & IV) (Rosemont, IL) Trimethoprim Antibacterial Trimethoprim/sulfa Antibacterial Piritrexim Burroughs Wellcome PCP treatment Pentamidine Fisons Corporation PCP prophylaxis Isethionate for Inhalation Spiramycin Rhone-Poulenc Cryptosporidial diarrhea Intraconazole- Janssen-Pharm. Histoplasmosis; R51211 cryptococcal meningitis Trimetrexate Warner-Lambert PCP Daunorubicin NeXstar, Sequus Kaposi's sarcoma Recombinant Human Ortho Pharm. Corp. Severe anemia Erythropoietin assoc. with AZT therapy Recombinant Human Serono AIDS-related Growth Hormone wasting, cachexia Megestrol Acetate Bristol-Myers Squibb Treatment of anorexia assoc. W/AIDS Testosterone Alza, Smith Kline AIDS-related wasting Total Enteral Norwich Eaton Diarrhea and Nutrition Pharmaceuticals malabsorption related to AIDS

[0268] Therapeutically effective means the amount of agent required to provide a meaningful patient benefit as understood by practitioners in the field of AIDS and HIV infection. In general, the goals of therapeutically effective treatment include suppression of viral load, restoration and preservation of immunologic function, improved quality of life, and reduction of HIV-related morbidity and mortality.

[0269] Patient means a person infected with the HIV virus and suitable for therapy as understood by practitioners in the field of AIDS and HIV infection.

[0270] Treatment, therapy, regimen, HIV infection, ARC, AIDS and related terms are used as understood by practitioners in the field of AIDS and HIV infection.

Methods of Synthesis

[0271] The compounds of the invention according to the various aspects can be made by various methods available in the art, including those of the following schemes in the specific examples which follow. The structure numbering and variable numbering shown in the synthetic schemes may be distinct from, and should not be confused with, the structure or variable numbering in the claims or the rest of the specification. The variables in the schemes are meant only to illustrate how to make some of the compounds of the invention.

[0272] Abbreviations used in the schemes generally follow conventions used in the art. Some specific chemical abbreviations used in the examples are defined as follows: DMF for N,N-dimethylformamide; MeOH for methanol; Ar for aryl; TFA for trifluoroacetic acid; BOC for t-butoxycarbonate, DMSO for dimethylsulfoxide; h for hours; rt for room temperature or retention time (context will dictate); min for minutes; EtOAc for ethyl acetate; THF for tetrahydrofuran; Et.sub.2O for diethyl ether; DMAP for 4-dimethylaminopyridine; DCE for 1,2-dichloroethane; ACN for acetonitrile; DME for 1,2-dimethoxyethane; HATU for (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) DIEA for diisopropylethylamine.

[0273] Certain other abbreviations as used herein, are defined as follows: 1 for once, 2 for twice, 3 for thrice, C. for degrees Celsius, eq for equivalent or equivalents, g for gram or grams, mg for milligram or milligrams, L for liter or liters, mL for milliliter or milliliters, 4 for microliter or microliters, N for normal, M for molar, mmol for millimole or millimoles, min for minute or minutes, h for hour or hours, rt for room temperature, RT for retention time, atm for atmosphere, psi for pounds per square inch, conc. for concentrate, sat or sat'd for saturated, MW for molecular weight, mp for melting point, ee for enantiomeric excess, MS or Mass Spec for mass spectrometry, ESI for electrospray ionization mass spectroscopy, HR for high resolution, HRMS for high resolution mass spectrometry, LCMS for liquid chromatography mass spectrometry, HPLC for high pressure liquid chromatography, RP HPLC for reverse phase HPLC, TLC or tic for thin layer chromatography, NMR for nuclear magnetic resonance spectroscopy, .sup.1H for proton, 8 for delta, s for singlet, d for doublet, t for triplet, q for quartet, m for multiplet, br for broad, Hz for hertz, and , , R, S, E, and Z are stereochemical designations familiar to one skilled in the art.

EXAMPLES

[0274] The following examples illustrate typical syntheses of the compounds of Formulas I, II, and III, as described generally above. These examples are illustrative only and are not intended to limit the disclosure in any way. The reagents and starting materials are readily available to one of ordinary skill in the art.

Chemistry

Typical Procedures and Characterization of Selected Examples:

[0275] Unless otherwise stated, solvents and reagents were used directly as obtained from commercial sources, and reactions were performed under a nitrogen atmosphere. Flash chromatography was conducted on Silica gel 60 (0.040-0.063 particle size; EM Science supply). .sup.1H NMR spectra were recorded on Bruker DRX-500f at 500 MHz (or Bruker AV 400 MHz, Bruker DPX-300B or Varian Gemini 300 at 300 MHz as stated). The chemical shifts were reported in ppm on the scale relative to TMS=0. The following internal references were used for the residual protons in the following solvents: CDCl.sub.3 (.sub.H 7.26), CD.sub.3OD (.sub.H 3.30), Acetic-d4 (Acetic Acid d.sub.4) (.sub.H 11.6, 2.07), DMSO mix or DMSO-D6_CDCl.sub.3 ((.sub.H 2.50 and 8.25) (ratio 75%:25%), and DMSO-D6 (.sub.H 2.50). Standard acronyms were employed to describe the multiplicity patterns: s (singlet), br. s (broad singlet), d (doublet), t (triplet), q (quartet), m (multiplet), b (broad), app (apparent). The coupling constant (J) is in Hertz. All Liquid Chromatography (LC) data were recorded on a Shimadzu LC-10AS liquid chromatograph using a SPD-10AV UV-Vis detector with Mass Spectrometry (MS) data determined using a Micromass Platform for LC in electrospray mode.

SECTION 1EXAMPLES

LC/MS Methods

Method 1A

[0276] Start % B=0, Final % B=100 over 2 minute gradient, hold at 100% B Flow Rate=5 mL/min [0277] Wavelength=220 nm [0278] Solvent A=95% water, 5% acetonitrile, 10 mM ammonium acetate [0279] Solvent B=5% water, 95% acetonitrile, 10 mM ammonium acetate [0280] Column=Phenomenex Luna C18, 10 m, 3.050 mm S10

Method 2A

[0281] Start % B=0, Final % B=100 over 2 minute gradient, hold at 100% B [0282] Flow Rate=4.0 mL/min [0283] Wavelength=220 nm [0284] Solvent A=90% water, 10% acetonitrile, 0.1% TFA [0285] Solvent B=10% water, 90% acetonitrile, 0.1% TFA [0286] Column=Sunfire C18, 5 m, 4.650 mm

Method 3A

[0287] Start % B=0, Final % B=100 over 2 minute gradient, hold at 100% B [0288] Flow Rate=4 mL/min [0289] Wavelength=220 nm [0290] Solvent A=95% water, 5% methanol, 10 mM ammonium acetate [0291] Solvent B=5% water, 95% methanol, 10 mM ammonium acetate [0292] Column=Phenomenex Luna C18, 10 m, 3.050 mm S10

Method 4A

[0293] Start % B=30, Final % B=95 over 10 minute gradient, hold at 95% B [0294] Flow Rate=1.2 mL/min [0295] Detection=ELS detection [0296] Solvent A=water, 0.1% TFA [0297] Solvent B=acetonitrile, 0.1% TFA [0298] Column=Cosmosil PYE 4.650 mm

Method 5A

[0299] Start % B=30, Final % B=95 over 6 minute gradient, hold at 95% B [0300] Flow Rate=1.5 mL/min [0301] Detection=ELS detection [0302] Solvent A=water, 10 mM ammonium acetate [0303] Solvent B=acetonitrile, 10 mM ammonium acetate [0304] Column=Supelco Ascentis 7550 mm 5 M C18

Method 6A

[0305] Start % B=10, Final % B=95 over 12 minute gradient, hold at 95% B [0306] Flow Rate=1 mL/min [0307] Wavelength=220 nm [0308] Solvent A=water with 10 mM ammonium acetate [0309] Solvent B=acetonitrile with 10 mM ammonium acetate [0310] Column=Waters Xbridge 4.6150 mm 5 M C18

Prep HPLC Purification Methods

Method 1

[0311] Start % B=10, Final % B=95 over 22.5 minute gradient, hold at 95% B [0312] Flow Rate=20.0 mL/min [0313] Detection=ELS detection [0314] Solvent A=water, 10 mM ammonium hydroxide [0315] Solvent B=acetonitrile, 10 mM ammonium hydroxide [0316] Column=Waters Xbridge 21.2150 mm 5 M C18

Method 2

[0317] Start % B=10, Final % B=95 over 22.5 minute gradient, hold at 95% B [0318] Flow Rate=20.0 mL/min [0319] Detection=ELS detection [0320] Solvent A=water, 0.1% TFA [0321] Solvent B=acetonitrile, 0.1% TFA [0322] Column=Cosmosil PYE 21.2150 mm

Method 3

[0323] Start % B=10, Final % B=95 over 4 minute gradient, hold at 95% B [0324] Flow Rate=20.0 mL/min [0325] Detection=ELS detection [0326] Solvent A=water, 10 mM Ammonium acetate [0327] Solvent B=acetonitrile, 10 mM Ammonium acetate [0328] Column=Waters Xbridge 21.2150 mm 5 M C18

Method 4

[0329] Start % B=10, Final % B=95 over 22.5 minute gradient, hold at 95% B [0330] Flow Rate=20.0 mL/min [0331] Detection=ELS detection [0332] Solvent A=water, 0.1% Formic acid [0333] Solvent B=acetonitrile, 0.1% Formic acid [0334] Column=Cosmosil PYE 21.2150 mm

Preparation of Key Intermediates

Preparation of ((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)docosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-9a-yl)methanol

[0335] ##STR00067##

[0336] Step 1. Preparation of (1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR,E)-benzyl 9-(hydroxyimino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysene-3a-carboxylate.

[0337] To a solution of (1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)-benzyl 5a,5b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahdro-1H-cyclopenta[a]chrysene-3a-carboxylate (3.0 g, 5.51 mmol) prepared as described in WO2011/153315 and potassium hydroxide (1.545 g, 27.5 mmol) in methanol (50 mL) was added hydroxylamine hydrochloride (0.765 g, 11.01 mmol) followed by toluene (30 mL). The mixture was heated to reflux for 15 h, then was cooled to rt. The solvent was removed under reduced pressure and the residue was diluted with water then extracted with diethyl ether three times. The organic layers were dried over magnesium sulfate, filtered and concentrated under reduced pressure to give the title product (3.03 g, 5.41 mmol, 98% yield) as a white solid. .sup.1H NMR (500 MHz, chloroform-d) 7.79 (br. s., 1H), 7.39-7.28 (m, 5H), 5.15 (d, J=12.2 Hz, 1H), 5.08 (d, J=12.5 Hz, 1H), 4.72 (d, J=2.1 Hz, 1H), 4.59 (dd, J=2.1, 1.2 Hz, 1H), 3.01 (td, J=11.0, 4.6 Hz, 1H), 2.97-2.90 (m, 1H), 2.30-2.15 (m, 3H), 1.94-1.81 (m, 2H), 1.80-1.72 (m, 1H), 1.67 (s, 3H), 1.11 (s, 3H), 1.02 (s, 3H), 0.92 (s, 3H), 0.89 (s, 3H), 0.78 (s, 3H), 1.72-0.73 (m, 17H).

[0338] Step 2. Preparation of (7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-benzyl 5,5,7a,7b,14b-pentamethyl-3-oxo-12-(prop-1-en-2-yl)docosahydrocyclopenta[7,8]phenanthro[2,1-c]azepine-9a-carboxylate.

[0339] To a solution of (1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR,E)-benzyl 9-(hydroxyimino)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysene-3a-carboxylate (3.0 g, 5.36 mmol) in THF (50 mL) was added lithium hydroxide (0.257 g, 10.72 mmol). The mixture was stirred at rt for 20 minutes then 2-mesitylenesulfonyl chloride (5.86 g, 26.8 mmol) was added portionwise over 30 minutes. The mixture was stirred for 1 h at rt then was heated to 60 C. for 22 h. The mixture was cooled to rt, diluted with water (150 mL) and extracted with ether (3150 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography using a 90 g silica gel column and a 0-75% ethyl acetate in hexanes gradient. The title product (1.78 g, 3.02 mmol, 56.4% yield) was isolated as a white foam. LCMS: m/e 560.5 (M+H).sup.+, 2.13 min (method 1A).

[0340] Step 3. Preparation of (5aR,7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-3(2H)-one.

[0341] To a solution of benzyl (5aR,7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-5,5,7a,7b,14b-pentamethyl-3-oxo-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepine-9a(1H)-carboxylate (0.25 g, 0.447 mmol) in THF (2 mL) was added LAH (1M in THF) (0.893 mL, 0.893 mmol) dropwise. The mixture was stirred at rt for 3.5 h. The mixture was carefully quenched with water, neutralized with saturated aqueous ammonium chloride and extracted with ether (310 mL). The combined organic layer were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography using a 0-10% methanol in dichloromethane gradient. The title compound was isolated as a white solid (0.095 g, 0.208 mmol, 47% yield). LCMS: m/e 456.44 (M+H).sup.+, 2.03 min (method 2A).

[0342] Step 4. To a solution of (7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-benzyl 5,5,7a,7b,14b-pentamethyl-3-oxo-12-(prop-1-en-2-yl)docosahydrocyclopenta[7,8]phenanthro[2,1-c]azepine-9a-carboxylate (0.25 g, 0.447 mmol) in THF (2 mL) was added LAH (1M solution in THF) (1 mL, 1.000 mmol) dropwise. The mixture was heated to 60 C. After 17 h of heating, the mixture was cooled to rt. An additional 0.5 mL of 1M LAH solution was added and the mixture was heated to 60 C. for 6 h. The reaction was quenched by carefully adding water. The mixture was extracted with ether (225 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was used in the next step with no additional purification. LCMS: m/e 442.4 (M+H).sup.+, 1.36 min (method 2A).

Preparation of benzyl(1R,3aS,5aR,5bR,7aR,10aR,10bR,12aR,12bR)-5a,5b,8,8,10a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)octadecahydrodicyclopenta[a,i]phenanthrene-3a(1H)-carboxylate

[0343] ##STR00068##

[0344] Step 1: Preparation of benzyl(1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR,Z)-10-(hydroxymethylene)-5a,5b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysene-3a-carboxylate.

[0345] To a solution of benzyl (1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR)-5a,5b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahydro-3aH-cyclopenta[a]chrysene-3a-carboxylate (10.87 g, 19.95 mmol) in toluene (150 mL) was added pyridine (15.0 mL) followed by sodium hydride (7.0 g, 175 mmol) (portionwise over 15 minutes). The mixture was stirred for five minutes and ethyl formate (32.5 mL, 399 mmol) was added dropwise followed by 5 drops of methanol. The mixture was stirred at rt for 6 h, then was carefully quenched with 0.1N HCl (100 mL). The mixture was diluted further with water (100 mL) and extracted with diethyl ether (3150 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title product (11.43 g, 19.95 mmol, 100% yield), as a thick, yellow oil. .sup.1H NMR (400 MHz, chloroform-d) 14.86 (d, J=3.3 Hz, 1H), 8.58 (d, J=3.0 Hz, 1H), 7.42-7.29 (m, 5H), 5.20-5.08 (m, 2H), 4.75 (d, J=2.3 Hz, 1H), 4.61 (dd, J=2.3, 1.3 Hz, 1H), 3.04 (td, J=10.9, 4.9 Hz, 1H), 2.38-2.20 (m, 3H), 1.70 (s, 3H), 1.18 (s, 3H), 1.10 (s, 3H), 0.97 (s, 3H), 0.82 (s, 6H), 2.01-0.74 (m, 19H).

[0346] Step 2: Preparation of 2-((3R,4R,5R,8R,9R,10R,13S,14R,15R)-13-((benzyloxy)carbonyl)-4-(carboxymethyl)-4,9,10-trimethyl-15-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[a]phenanthren-3-yl)-2-methylpropanoic acid. A suspension of benzyl (1R,3aS,5aR,5bR,7aR,11aR,11bR,13aR,13bR,Z)-10-(hydroxymethylene)-5a,5b,8,8,11a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)icosahdro-3aH-cyclopenta[a]chrysene-3a-carboxylate (11.43 g, 19.95 mmol) in potassium hydroxide (2 M solution) (150 mL, 299 mmol) and methanol (50 mL) was heated to 60 C. To the suspension was added hydrogen peroxide (30%) (61.1 mL, 599 mmol) dropwise. The mixture was stirred for 3 h at 60 C., then was cooled to rt, acidified with 1N HCl to pH=1 and extracted with ether (3150 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was used in the next step with no additional purification. LC/MS: m/e 591.47 (MH).sup., 1.43 min (method 1A).

[0347] Step 3: Preparation of benzyl(3R,4R,5R,8R,9R,10R,13S,14R,15R)-3-(1-methoxy-2-methyl-1-oxopropan-2-yl)-4-(2-methoxy-2-oxoethyl)-4,9,10-trimethyl-15-(prop-1-en-2-yl)hexadecahydro-13H-cyclopenta[a]phenanthrene-13-carboxylate.

[0348] The crude residue from the previous step was dissolved in Toluene (100 mL) and methanol (25 mL) and was cooled to 0 C. To the solution was added TMS-Diazomethane (23.94 mL, 47.9 mmol). The mixture was warmed to rt. After stirring the mixture for 3 h at rt, it was quenched with sat. aq. sodium bicarbonate (300 mL) and was extracted with diethyl ether (3150 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was used directly in the next step with no additional purification. LC/MS: m/e 621.48 (M+H).sup.+, 2.28 min (method 1A).

[0349] Step 4: To a mixture of the product from step 3 (12.39 g, 19.95 mmol) in methanol (200 mL) was added potassium hydroxide (22.39 g, 399 mmol). The mixture was heated to reflux for 16 h then was cooled to rt. The solvent was removed under reduced pressure, the residue was diluted with water (300 mL) and was extracted with ether (3150 mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated under reduced pressure. Benzyl (1R,3aS,5aR,5bR,7aR,10aR,10bR,12aR,12bR)-5a,5b,8,8,10a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)octadecahydrodicyclopenta[a,i]phenanthrene-3a(1H)-carboxylate was isolated as a thick yellow oil which was used in the next step with no additional purification. .sup.1H NMR (500 MHz, chloroform-d) 7.42-7.29 (m, 5H), 5.19-5.08 (m, 2H), 4.73 (d, J=2.1 Hz, 1H), 4.60 (dd, J=2.3, 1.4 Hz, 1H), 3.02 (td, J=11.0, 4.9 Hz, 1H), 1.68 (s, 3H), 1.01 (s, 3H), 1.00 (s, 3H), 0.96 (s, 3H), 0.82 (d, J=0.9 Hz, 3H), 0.78 (s, 3H), 2.40-0.67 (m, 22H).

Preparation of ((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahdro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-8a-yl)methanol

[0350] ##STR00069##

[0351] Step 1: Preparation of benzyl(1R,3aS,5aR,5bR,7aR,10aR,10bR,12aR,12bR,E)-9-(hydroxyimino)-5a,5b,8,8,10a-pentamethyl-1-(prop-1-en-2-yl)octadecahydrodicyclopenta[a]phenanthrene-3a(1H)-carboxylate.

[0352] To a solution of benzyl (1R,3aS,5aR,5bR,7aR,10aR,10bR,12aR,12bR)-5a,5b,8,8,10a-pentamethyl-9-oxo-1-(prop-1-en-2-yl)octadecahydrodicyclopenta[a,i]phenanthrene-3a(1H)-carboxylate (5.3 g, 9.99 mmol) in toluene (100 mL) was added potassium hydroxide (2.80 g, 49.9 mmol) followed by hydroxylamine HCl (1.388 g, 19.97 mmol). The mixture was heated to reflux with a dean-stark trap containing 4A molecular sieves attached. After 3 h of heating, the mixture was cooled to rt. Starting material still remained while a new peak was visible by TLC. To the mixture was added 1.6 g of hydroxylamine HCl and 20 mL of MeOH. The mixture was attached to the Dean-Stark trap and was heated to reflux. After 19 h of heating, the mixture was cooled to rt. TLC indicated starting material still remained. The Dean-Stark trap was empties of solvent and the molecular sieves were replaced with dry sieves. To the mixture was added 20 mL of MeOH and and 1.4 g of hydroxylamine HCl. The mixture was heated to reflux overnight. TLC indicated starting material still remained. The Dean-Stark trap was empties of solvent and the molecular sieves were replaced with dry sieves. To the mixture was added 20 ML of MeOH and and 1.4 g of hydroxylamine HCl. The mixture was again heated to reflux overnight. TLC indicated starting material still remained. To the mixture was added 20 ML of MeOH and and 1.4 g of hydroxylamine HCl. The mixture was heated to reflux for 6 h, then was cooled to rt. TLC showed no remaining starting material. Solids were removed from the mixture by filtration. The filtrate was partitioned with water (150 mL) and extracted with ethyl acetate (3125 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography using a 0-20% ethyl acetate in hexanes gradient. The fractions containing the product were combined and concentrated under reduced pressure to give the title product (4.53 g, 8.30 mmol, 83% yield) as an off-white foam. LC/MS: m/e 546.44 (M+H).sup.+, 2.37 min (method 1A).

[0353] Step 2: Preparation of benzyl(4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-2-oxo-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carboxylate.

[0354] To a solution of benzyl (1R,3aS,5aR,5bR,7aR,10aR,10bR,12aR,12bR,E)-9-(hydroxyimino)-5a,5b,8,8,10a-pentamethyl-1-(prop-1-en-2-yl)octadecahydrodicyclopenta[a,i]phenanthrene-3a(1H)-carboxylate (5.2 g, 9.53 mmol) in toluene (125 mL) was added 2,4,6-triisopropylbenzene-1-sulfonyl chloride (8.3 g, 27.4 mmol), followed by DIEA (3.4 mL, 19.52 mmol) and a catalytic amount of 4-DMAP (25 mg). The mixture was stirred for 2 hours at room temperature before it was heated in an oil bath at 95 C. After heating the mixture overnight, it was diluted with 50 mL 0.5N HCl. The organic phase was separated and washed with water. The aq. HCl phase was extracted with ethyl acetate (225 mL). The organic layers were combined, concentrated and purified on a 90 gm silica gel column eluted with mixtures of ethyl acetate and hexanes to give 4.1 gm (79%) of the titled compound as a white solid. LC/MS: m/e 546.49 (M+H).sup.+, 3.78 min (method 2A); .sup.1H NMR (500 MHz, CDCl.sub.3) 7.41-7.30 (m, 5H), 5.62 (s, 1H), 5.21-5.07 (m, 2H), 4.75 (s, 1H), 4.63 (s, 1H), 3.03 (td, J=10.9, 4.4 Hz, 1H), 2.43 (d, J=16.8 Hz, 1H), 2.31 (d, J=12.8 Hz, 1H), 2.27-2.18 (m, 1H), 1.98-1.84 (m, 2H), 1.80-1.71 (m, 2H), 1.70 (s, 3H), 1.62 (t, J=11.4 Hz, 1H), 1.50-1.37 (m, 9H), 1.37-1.26 (m, 4H), 1.25 (s, 3H), 1.15 (s, 3H), 1.10-1.01 (m, 1H), 0.98 (s, 3H), 0.95 (s, 3H), 0.79 (s, 3H); .sup.13C NMR (126 MHz, CDCl.sub.3) 175.8, 170.8, 150.4, 136.5, 128.6, 128.4, 128.2, 109.9, 65.9, 56.6, 55.4, 51.6, 49.4, 48.5, 47.4, 47.0, 42.5, 40.6, 38.2, 37.0, 36.9, 33.9, 33.1, 32.1, 30.7, 29.7, 25.4, 21.6, 21.2, 20.2, 19.5, 16.8, 15.4, 14.7.

[0355] Step 3: To a solution of benzyl (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-2-oxo-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carboxylate (5a, 4.34 gm, 7.95 mmol) in THF (90 mL) at 0 C. was added LiAlH.sub.4 (2.0 gm, 52.7 mmol) in small portions. The mixture was warmed to room temperature for 30 minutes then was further warmed to 65 C. for 48 hours. The reaction mixture was quenched by slow addition of 20% w/w solution of sodium hydroxide until a free-flowing, white suspension was formed. The mixture was filtered and concentrated into a syrup. It was redissolved in chloroform then was passed through a short bed of silica gel which was washed with mixtures of isopropanol and methylene chloride to give ((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-8a-yl)methanol (2.9 gm, 85%) after concentration. LC/MS: m/e 428.24 (M+H).sup.+, 1.87 min (method 3A); .sup.1H NMR (400 MHz, CDCl.sub.3) 4.70 (d, J=2.0 Hz, 1H), 4.60 (dd, J=2.3, 1.3 Hz, 1H), 3.81 (d, J=9.5 Hz, 1H), 3.35 (d, J=11.0 Hz, 1H), 3.10-2.95 (m, 1H), 2.97-2.83 (m, 1H), 2.41 (td, J=10.8, 5.8 Hz, 1H), 2.00 (s, 3H), 1.95 (ddd, J=13.5, 7.1, 3.0 Hz, 2H), 1.87 (dd, J=12.0, 8.0 Hz, 2H), 1.68-1.61 (m, 2H), 1.61-1.53 (m, 2H), 1.49 (d, J=10.8 Hz, 2H), 1.44-1.34 (m, 6H), 1.25 (dd, J=13.3, 3.3 Hz, 2H), 1.19 (s, 3H), 1.15 (d, J=5.0 Hz, 1H), 1.11 (s, 3H), 1.09-1.08 (m, 3H), 1.05 (s, 3H), 1.00 (s, 3H), 0.93 (s, 3H); .sup.13C NMR (101 MHz, CDCl.sub.3) 150.1, 109.4, 60.1, 55.2, 53.6, 49.6, 48.3, 47.4, 47.4, 42.4, 40.6, 38.7, 36.9, 36.7, 35.6, 33.6, 33.4, 31.4, 29.3, 28.8, 26.6, 24.7, 24.5, 20.1, 19.1, 18.7, 15.6, 15.5, 14.4.

General Method A for Amide Synthesis

[0356] ##STR00070##

[0357] To a vial containing a solution of ((5aR,7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-9a(1H)-yl)methanol (450 mg, 1.02 mmol) in dichloromethane (20.0 mL) was added Hunig's base (1.78 mL, 10.19 mmol) to prepare a stock solution of the template. To separate vials containing the reactant acid chlorides (1.019 mmol) was added 2.0 mL of the stock solution of template. Each vial was sealed and shaken vigorously overnight at room temperature. Once analysis showed the reactions were complete, they were concentrated at 35 C. Each residue was diluted with 1.0 mL of methanol, and was sonicated until all solids dissolved. To each vial was added 0.401 mL of 2M potassium carbonate solution. The vials were heated to 60 C. overnight. Analysis at this point showed a mixture of N and 0 alkylated products that were purified by prep HPLC equipped with an ELS detector to initiate collection. Several of the compounds were not completely hydrolyzed using the above conditions and had to be further subjected to hydrolysis conditions to complete the saponification.

Example 1

Preparation of 3-((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)-3-oxopropanoic acid

[0358] ##STR00071##

[0359] The preparation of 3-oxo-3-(((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-9a(1H)-yl)methoxy)propanoic acid and 3-((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)-3-oxopropanoic acid was accomplished using general method A for amide synthesis. Methyl 3-chloro-3-oxopropanoate (0.139 g, 1.019 mmol) was used as the reactant acid chloride. The material was purified using prep HPLC purification method 1, then the individual products were repurified using prep HPLC purification method 2. LCMS: m/e 528.50 (M+H).sup.+, 7.43 min (method 4A).

Example 2

Preparation of 3-((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)docosahydrocyclopenta[7,8]phenanthro[2,1-c]azepine-4-carbonyl)benzoic acid

[0360] ##STR00072##

[0361] The preparation of 3-((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)docosahydrocyclopenta[7,8]phenanthro[2,1-c]azepine-4-carbonyl)benzoic acid was accomplished using general method A for amide synthesis. Methyl 3-(chlorocarbonyl)benzoate (0.202 g, 1.019 mmol) was used as the reactant acid chloride. The material was purified using prep HPLC purification method 1. LCMS: m/e 590.55 (M+H).sup.+, 7.79 min (method 4A).

Example 3

Preparation of 4-((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)-4-oxobutanoic acid

[0362] ##STR00073##

[0363] The preparation of 4-((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)-4-oxobutanoic acid was accomplished using general method A for amide synthesis. Ethyl 4-chloro-4-oxobutanoate (0.168 g, 1.019 mmol) was used as the reactant acid chloride. The material was purified using prep HPLC purification method 1. LCMS: m/e 542.50 (M+H).sup.+, 7.03 min (method 4A).

Example 4

Preparation of 6-((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)-6-oxohexanoic acid

[0364] ##STR00074##

[0365] The preparation of 6-((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)-6-oxohexanoic acid was accomplished using general method A for amide synthesis. Methyl 6-chloro-6-oxohexanoate (0.168 g, 1.019 mmol) was used as the reactant acid chloride. The material was purified using prep HPLC purification method 1. LCMS: m/e 570.55 (M+H).sup.+, 7.26 min (method 4A).

General Method B for Amide Synthesis

[0366] ##STR00075##

[0367] To a vial containing ((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-8a-yl)methanol (0.480 g, 1.122 mmol) and DCE (24 mL) was added DIEA (0.588 mL) to prepare the stock solution of template. To vials containing the reactant acid chlorides (1.0 equiv., 0.094 mmol per reaction) was added 2.0 mL of the stock solution and the mixtures were shaken vigorously overnight at rt. The reaction mixtures were concentrated then diluted with 2.0 mL of DMF and sonicated to fully dissolve the mixtures. To each vial was added lithium hydroxide monohydrate (10.2 equiv, 39.0 mg, 0.93 mmol) and water (1 mL). The mixtures were allowed to shake at rt for 2 days then were concentrated. Each mixture was diluted with methanol (1.2 mL) and DMF (0.4 mL) and was shaken vigorously. 37% HCl (0.05 mL) was added and the mixtures were sonicated until solids dissolved. Each mixture was then purified by prep HPLC.

Example 5

Preparation of 3-((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-3-carbonyl)benzoic acid

[0368] ##STR00076##

[0369] Preparation of 3-((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-3-carbonyl)benzoic acid was accomplished using the general method B for amide synthesis. 3-(chlorocarbonyl)benzoic acid methyl ester was used as the reactant acid chloride. The material was purified using prep HPLC purification method 3. LCMS: m/e 576.34 (M+H).sup.+, 9.02 min (method 6A).

Example 6

Preparation of 2-((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2-oxoacetic acid

[0370] ##STR00077##

[0371] Preparation of 2-((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2-oxoacetic acid was accomplished using the general method B for amide synthesis. Ethyl 2-chloro-2-oxoacetate was used as the reactant acid chloride. The material was purified using prep HPLC purification method 3. LCMS: m/e 500.27 (M+H).sup.+, 7.59 min (method 6A).

Example 7

Preparation of 3-((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-3-oxopropanoic acid

[0372] ##STR00078##

[0373] The preparation of 3-((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-3-oxopropanoic acid was accomplished using the general method B for amide synthesis. Methyl 3-chloro-3-oxopropanoate was used as the reactant acid chloride. The material was purified using prep HPLC purification method 4. LCMS: m/e 514.28 (M+H).sup.+, 7.92 min (method 6A).

Example 8

Preparation of 5-((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-5-oxopentanoic acid

[0374] ##STR00079##

[0375] To a mixture of ((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-8a-yl)methanol (0.051 g, 0.119 mmol) in DCE (2 mL) was added Hunig's Base (0.104 mL, 0.595 mmol) followed by methyl 4-(chloroformyl)butyrate (0.082 mL, 0.595 mmol). The mixture stirred at for 17 h then was poured into 1N HCl (5 mL) and was extracted with dichloromethane (35 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue (82 mg, 0.12 mmol) was diluted with methanol (2 mL) and water (1 mL) and potassium carbonate (0.083 g, 0.60 mmol) was added. The mixture was heated to 60 C. for 26 h, then was further stirred art for 4 days. 1.5 mL of 1N NaOH was then added and the mixture was heated to 60 C. After 4.5 h of heating, the mixture was cooled to rt, acidified with 1N HCl and extracted with dichloromethane (310 mL). The organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography using a 0-5% methanol in dichloromethane gradient. The product did not elute, so the column was further washed with a 5-10% methanol in dichloromethane gradient with 0.1% acetic acid added. The fractions containing the title product were combined and concentrated to give a clear, colorless film (0.018 g, 0.033 mmol, 28% yield). LCMS: m/e 542.48 (M+H).sup.+, 1.28 min (method 1A).

Example 9

Preparation of 4-((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-4-oxobutanoic acid

[0376] ##STR00080##

[0377] Step 1. Preparation of methyl 4-((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-4-oxobutanoate

[0378] To a mixture of ((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-8a-yl)methanol (0.05 g, 0.117 mmol) in DCE (2 mL) was added Hunig's Base (0.061 mL, 0.351 mmol) followed by 3-carbomethoxypropionyl chloride (0.015 mL, 0.123 mmol). The mixture stirred at rt for 17 h then was poured into 1N HCl (4 mL) and extracted with dichloromethane (33 mL). The combined organic layers were dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography using a 0-30% ethyl acetate in hexanes gradient and a 12 g silica gel column. The fractions containing the product were combined and concentrated to give the title product (43.5 mg, 0.076 mmol, 65.2% yield) as a white solid. LCMS: m/e 542.48 (M+H).sup.+, 1.83 min (method 1A).

[0379] Step 2. To a solution of 4-((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-4-oxobutanoate (32 mg, 0.059 mmol) in DMF (2 mL) was added lithium hydroxide monohydrate (25 mg, 0.596 mmol). The mixture was diluted with water (1 mL) and stirred overnight at rt. After stirring the mixture for 24.5 h at rt, the reaction was quenched with 1 mL of 1N HCl and was concentrated under reduced pressure. The residue was purified by flash chromatography using a 0-5% methanol in dichloromethane gradient with 0.1% acetic acid on a 12 g silica gel column. The title product (0.028 g, 0.053 mmol, 90% yield) was isolated as a white foam. LCMS: m/e 528.49 (M+H).sup.+, 1.33 min (method 1A).

Example 10

Preparation of 4-((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-3-carbonyl)benzoic acid

[0380] ##STR00081##

[0381] To a vial containing ((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-8a-yl)methanol (0.05 g, 0.117 mmol) was added terephthalic acid monomethyl ester chloride (0.026 g, 0.129 mmol). The mixture was diluted with DCE (2 mL) and Hunig's Base (0.061 mL, 0.351 mmol) and was stirred at rt overnight. The reaction was not complete, so an additional 0.015 g of terephthalic acid monomethyl ester chloride was added to the mixture and it was stirred at rt. After 4.5 h of stirring at rt, the reaction was still not complete so an additional 0.05 g of terephthalic acid monomethyl ester chloride was added and the mixture was warmed to 50 C. After 3 h of heating, the mixture was cooled to rt then stirred at rt for 3 days. The mixture was diluted with water (3 mL) and was extracted with dichloromethane (35 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude residue was diluted with 1,4-dioxane (4 mL) and water (1 mL). Lithium hydroxide monohydrate was added and the mixture was heated to 75 C. After 2 h of heating, the mixture was cooled to rt and was diluted with 5 mL of 1N HCl and then was extracted with dichloromethane (37 mL). The organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The title product was crystallized and isolated from hot dioxane, methanol and water as an off-white solid (0.0325 g, 0.056 mmol, 48% yield). LCMS: m/e 576.49 (M+H).sup.+, 2.00 min (method 3A).

General Method A for Sulfonamide Synthesis

[0382] ##STR00082##

[0383] To a vial containing a solution of ((5aR,7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-9a(1H)-yl)methanol (440 mg, 1.00 mmol) in dichloroethane (22.0 mL) was added Hunig's base (0.517 mL, 4.00 mmol) to prepare a stock solution of the template. To separate vials containing the reactant sulfonyl chlorides (0.095 mmol, 1.05 eq.) was added 2.0 mL of the stock solution of template. Each vial was sealed and shaken vigorously overnight at room temperature. Once analysis showed the reactions were complete, they were concentrated, diluted with DMF (2.0 mL) and lithium hydroxide monohydrate (39.0 mg, 0.93 mmol) was added followed by 1.0 mL of water. The vials were shaken vigorously overnight at rt. The mixtures were diluted with a small amount of methanol and shaken for another day at rt, then concentrated and diluted with methanol (1.2 mL) and DMSO (0.4 mL). The mixtures were shaken vigorously and 50 L of 37% HCl was added. The mixtures were sonicated to dissolve the solids and purified by prep HPLC to give the sulfonamide products.

Example 11

Preparation of 5-(((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)sulfonyl)furan-2-carboxylic acid

[0384] ##STR00083##

[0385] The preparation of 5-(((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)sulfonyl)furan-2-carboxylic acid was accomplished using the general method A for sulfonamide formation. 5-(chlorosulfonyl)furan-2-carboxylic acid methyl ester (0.02 g) was used as the reactant sulfonyl chloride. The material was purified using prep HPLC purification method 1. LCMS: m/e 616.38 (M+H).sup.+, 2.92 min (method 5A).

Example 12

Preparation of (E)-3-(4-(((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)sulfonyl)phenyl)acrylic acid

[0386] ##STR00084##

[0387] The preparation of (E)-3-(4-(((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)sulfonyl)phenyl)acrylic acid was accomplished using the general method A for sulfonamide formation. (E)-3-(4-(chlorosulfonyl)phenyl)acrylic acid (0.0235 g) was used as the reactant sulfonyl chloride. The material was purified using prep HPLC purification method 1. LCMS: m/e 652.47 (M+H).sup.+, 3.05 min (method 5A).

Example 13

Preparation of 3-(((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)sulfonyl)benzoic acid

[0388] ##STR00085##

[0389] The preparation of 3-(((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)sulfonyl)benzoic acid was accomplished using the general method A for sulfonamide formation. 3-(chlorosulfonyl)benzoic acid (0.021 g) was used as the reactant sulfonyl chloride. The material was purified using prep HPLC purification method 1. LCMS: m/e 626.42 (M+H).sup.+, 2.89 min (method 5A).

Example 14

Preparation of 4-(((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)sulfonyl)benzoic acid

[0390] ##STR00086##

[0391] The preparation of 4-(((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)sulfonyl)benzoic acid was accomplished using the general method A for sulfonamide formation. 4-(chlorosulfonyl)benzoic acid (0.021 g) was used as the reactant sulfonyl chloride. The material was purified using prep HPLC purification method 1. LCMS: m/e 626.40 (M+H).sup.+, 2.82 min (method 5A).

Example 15

Preparation of 2-(4-(((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)sulfonyl)phenyl)acetic acid

[0392] ##STR00087##

[0393] The preparation of 2-(4-(((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)sulfonyl)phenyl)acetic acid was accomplished using the general method A for sulfonamide formation. 2-(4-(chlorosulfonyl)phenyl)acetic acid (0.022 g) was used as the reactant sulfonyl chloride. The material was purified using prep HPLC purification method 1. LCMS: m/e 640.45 (M+H).sup.+, 3.06 min (method 5A).

Example 16

Preparation of 5-(((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)sulfonyl)-2-methylbenzoic acid

[0394] ##STR00088##

[0395] The preparation of 5-(((7aR,7bR,9aS,12R,12aR,12bR,14aR,14bR)-9a-(hydroxymethyl)-5,5,7a,7b,14b-pentamethyl-12-(prop-1-en-2-yl)icosahydrocyclopenta[7,8]phenanthro[2,1-c]azepin-4(1H)-yl)sulfonyl)-2-methylbenzoic acid was accomplished using the general method A for sulfonamide formation. 5-(chlorosulfonyl)-2-methylbenzoic acid (0.022 g) was used as the reactant sulfonyl chloride. The material was purified using prep HPLC purification method 1. LCMS: m/e 640.41 (M+H).sup.+, 2.99 min (method 5A).

General Method B for Sulfonamide Synthesis

[0396] ##STR00089##

[0397] The sulfonamide synthesis was run using the same reaction conditions as the amide synthesis method B above and the same stock solution of template. Instead of using acid chloride reactants, sulfonamides were prepared using the reactant sulfonyl chlorides. Workup and purification was run in parallel to the amide series following the same conditions.

Example 17

Preparation of 3-(((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)sulfonyl)benzoic acid

[0398] ##STR00090##

[0399] The preparation of 3-(((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahdro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)sulfonyl)benzoic acid was accomplished using the general method B for sulfonamide synthesis. 3-(chlorosulfonyl)benzoic acid was used as the reactant sulfonyl chloride. The material was purified using prep HPLC purification method 4. LCMS: m/e 612.26 (M+H).sup.+, 9.02 min (method 6A).

Example 18

Preparation of (E)-3-(4-(((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)sulfonyl)phenyl)acrylic acid

[0400] ##STR00091##

[0401] The preparation of (E)-3-(4-(((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)sulfonyl)phenyl)acrylic acid was accomplished using the general method B for sulfonamide synthesis. (E)-3-(4-(chlorosulfonyl)phenyl)acrylic acid was used as the reactant sulfonyl chloride. The material was purified using prep HPLC purification method 4. LCMS: m/e 638.35 (M+H).sup.+, 9.58 min (method 6A).

Example 19

Preparation of 2-(4-(((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)sulfonyl)phenyl)acetic acid

[0402] ##STR00092##

[0403] The preparation of 2-(4-(((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)sulfonyl)phenyl)acetic acid was accomplished using the general method B for sulfonamide synthesis. 2-(4-(chlorosulfonyl)phenyl)acetic acid was used as the reactant sulfonyl chloride. The material was purified using prep HPLC purification method 4. LCMS: m/e 626.33 (M+H).sup.+, 9.24 min (method 6A).

Example 20

Preparation of 4-(((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)sulfonyl)benzoic acid

[0404] ##STR00093##

[0405] The preparation of 4-(((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13 b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)sulfonyl)benzoic acid was accomplished using the general method B for sulfonamide synthesis. 4-(chlorosulfonyl)benzoic acid was used as the reactant sulfonyl chloride. The material was purified using prep HPLC purification method 4. LCMS: m/e 612.28 (M+H).sup.+, 8.94 min (method 6A).

Example 21

Preparation of 3-(((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)sulfonyl)thiophene-2-carboxylic acid

[0406] ##STR00094##

[0407] The preparation of 3-(((6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(hydroxymethyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)sulfonyl)thiophene-2-carboxylic acid was accomplished using the general method B for sulfonamide synthesis. Methyl 3-(chlorosulfonyl)thiophene-2-carboxylate was used as the reactant sulfonyl chloride. The material was purified using prep HPLC purification method 4. LCMS: m/e 618.26 (M+H).sup.+, 8.88 min (method 6A).

SECTION 2EXAMPLES

LC/MS Methods

Method 1B

[0408] Start % B=20; Final % B=100; gradient time=3 min [0409] Flow Rate=4 mL/min [0410] Wavelength=220 nm [0411] Solvent A=10% MeOH90% H.sub.2O0.1% TFA [0412] Solvent B=90% MeOH10% H.sub.2O0.1% TFA [0413] Column=Xbridge Phenyl 4.650 mm S5

Method 2B

[0414] Start % B=20; Final % B=100; gradient time=2 min [0415] Flow Rate=0.8 mL/min [0416] Wavelength=254 nm [0417] Solvent A=10% MeOH90% H.sub.200.1% TFA [0418] Solvent B=90% MeOH10% H.sub.200.1% TFA [0419] Column=Xbridge Phenyl 2.150 mm 2.5 m

Method 3B

[0420] Start % B=0; final % B=100; gradient time=2 min [0421] Flow Rate=1 mL/min [0422] Wavelength=220 nm [0423] Solvent A=10% MeOH90% H.sub.200.1% TFA [0424] Solvent B=90% MeOH10% H.sub.200.1% TFA [0425] Column=PHENOMENEX-LUNA 2.030 mm 3 m

Method 4B

[0426] Start % B=10; Final % B=100; gradient time=2 min [0427] Flow Rate=1 mL/min [0428] Wavelength=220 nm [0429] Solvent A=10% MeOH90% H.sub.200.1% TFA [0430] Solvent B=90% MeOH10% H.sub.200.1% TFA [0431] Column=PHENOMENEX-LUNA 2.030 mm 3 m

Method 5B

[0432] Start % B=20; Final % B=100; gradient time=2 min [0433] Flow Rate=4 mL/min [0434] Wavelength=220 nm [0435] Solvent A=10% MeOH90% H.sub.200.1% TFA [0436] Solvent B=90% MeOH10% H.sub.200.1% TFA [0437] Column 3=Xbridge Phenyl 4.650 mm S5

Method 6B

[0438] Start % B=10; Final % B=100; gradient time=2 min [0439] Flow Rate=0.8 mL/min [0440] Wavelength=220 nm [0441] Solvent A=10% MeOH90% H.sub.200.1% TFA [0442] Solvent B=90% MeOH10% H.sub.200.1% TFA [0443] Column 4=Xbridge C8 2.150 mm 2.5 m

Method 7B

[0444] Start % B=30; Final % B=100; gradient Time=2 min [0445] Flow Rate=1 ml/min [0446] Wavelength=220 nm [0447] Solvent A=10% MeOH90% H.sub.2O0.1% TFA [0448] Solvent B=90% MeOH10% H.sub.2O0.1% TFA [0449] Column=Phenomenex-Luna 2.030 mm 3 m

Method 8B

[0450] Start % B=20; Final % B=100 over 2 minute gradient, hold at 100% B [0451] Flow Rate=0.8 mL/min [0452] Wavelength=220 nm [0453] Solvent A=90% water, 10% methanol, 0.1% TFA [0454] Solvent B=10% water, 90% methanol, 0.1% TFA [0455] Column=Xbridge Phenyl 2.150 mm 2.5 M

Method 9B

[0456] Start % B=20; Final % B=100 over 2 minute gradient, hold at 100% B [0457] Flow Rate=1.0 mL/min [0458] Wavelength=220 nm [0459] Solvent A=90% water, 10% methanol, 0.1% TFA [0460] Solvent B=10% water, 90% methanol, 0.1% TFA [0461] Column=Phenomenex Luna 2.030 mm 3 M

Method 10B

[0462] Start % B=0; Final % B=100 over 2 minute gradient, hold at 100% B [0463] Flow Rate=1.0 mL/min [0464] Wavelength=220 nm [0465] Solvent A=95% water, 5% methanol, 10 mM ammonium acetate [0466] Solvent B=5% water, 95% methanol, 10 mM ammonium acetate [0467] Column=Phenomenex Luna 2.030 mm C18, 3 M

Method 11B

[0468] Start % B=0; Final % B=100 over 4 minute gradient, hold at 100% B [0469] Flow Rate=0.8 mL/min [0470] Wavelength=220 nm [0471] Solvent A=90% water, 10% methanol, 0.1% TFA [0472] Solvent B=10% water, 90% methanol, 0.1% TFA [0473] Column=Phenomenex C18 2.050 mm 3 M

Method 12B

[0474] Start % B=20; Final % B=100 over 4 minute gradient, hold at 100% B [0475] Flow Rate=0.8 mL/min [0476] Wavelength=220 nm [0477] Solvent A=90% water, 10% methanol, 0.1% TFA [0478] Solvent B=10% water, 90% methanol, 0.1% TFA [0479] Column=Phenomenex C18 2.050 mm 3 M

Preparative HPLC

[0480] All of the compounds prepared in this Section 2 were purified using the following HPLC method. [0481] Start % B=30; Final % B=100; Gradient time=8 min [0482] Flow Rate=25 mL/min

ELSD as External Detector

[0483] Solvent A=10 mM Ammonium Acetate in 95:5 H.sub.2O/CH.sub.3CN [0484] Solvent B=10 mM Ammonium Acetate in 5:95 H.sub.2O/CH.sub.3CN [0485] Column=Xbridge PREP phenyl OBD C18 19100 mm 5 m

Example 22

Preparation of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-(4-carboxyphenyl)-4,4,6a,6b,13b-pentamethyl-2-oxo-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carboxylic acid

[0486] ##STR00095##

[0487] Step 1. Preparation of Benzyl(4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-(4-(ethoxycarbonyl)phenyl)-4,4,6a,6b,13b-pentamethyl-2-oxo-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carboxylate.

[0488] To a mixture of benzyl (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-2-oxo-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carboxylate (66 mg, 0.121 mmol), ethyl 4-iodobenzoate (36.7 mg, 0.133 mmol), potassium metaphosphate (31.4 mg, 0.266 mmol) and copper(I) iodide (0.410 L, 0.012 mmol) in a small sealable tube was added N,N-dimethylethylenediamine (2.132 mg, 0.024 mmol) and toluene (2 mL). The slightly turbid, greenish blue suspension was purged with nitrogen several times and placed in an oil bath at 115 C. for 24 hours. The mixture was cooled to rt and was purified by silica gel chromatography eluted with mixtures of ethyl acetate and hexanes. The fractions containing the product were combined and concentrated to give the title product (9.9 mg, 11.8%). LC/MS: m/e 694.45 (M+H).sup.+, 4.41 min (method 1B). .sup.1H NMR (400 MHz, CDCl.sub.3) 8.15-7.94 (m, 2H), 7.51-7.24 (m, 3H), 5.27-5.03 (m, 2H), 4.72 (d, J=1.8 Hz, 1H), 4.59 (d, J=1.3 Hz, 1H), 4.39 (q, J=7.1 Hz, 2H), 3.44-3.28 (m, 2H), 3.03 (td, J=10.9, 4.7 Hz, 1H), 2.40-2.19 (m, 2H), 2.01-1.81 (m, 2H), 1.80-1.66 (m, 1H), 1.68 (s, 3H), 1.66-1.57 (m, 2H), 1.54-1.37 (m, 10H), 1.41 (t, J=7.05 Hz, 3H), 1.34 (dd, J=13.5, 3.4 Hz, 2H), 1.31-1.21 (m, 3H), 1.28 (s, 3H), 1.23 (s, 3H), 1.17 (d, J=13.1 Hz, 1H), 1.13-0.96 (m, 1H), 1.09 (s, 3H), 1.00 (s, 3H), 0.85 (s, 3H).

[0489] Step 2. Preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-((benzyloxy)carbonyl)-4,4,6a,6b,13b-pentamethyl-2-oxo-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)benzoic acid

[0490] To a solution of benzyl (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-(4-(ethoxycarbonyl)phenyl)-4,4,6a,6b,13b-pentamethyl-2-oxo-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carboxylate (0.015 g, 0.022 mmol) in 1,4-dioxane (2 mL) was added 1N of NaOH (0.086 ml, 0.086 mmol) at rt. The resulted solution was stirred at 70 C. for 2 h. The reaction mixture was cooled to rt, then purified by Prep HPLC. The fractions containing title compound were combined and concentrated under reduced pressure to yield white solid (14 mg, 97%). MS m/e 666.38 (M+H).sup.+, 3.29 min (method 5B).

[0491] Step 3. To a solution of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-((benzyloxy)carbonyl)-4,4,6a,6b,13b-pentamethyl-2-oxo-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)benzoic acid (14 mg, 0.021 mmol) in DCE (3.5 mL) was added TEA (4.69 L, 0.034 mmol), tert-butyldimethylsilane (4.89 mg, 0.042 mmol) and palladium(II) acetate (1.180 mg, 5.26 mol). The mixture was flushed with nitrogen and heated to 60 C. After 2.5 h the mixture was cooled to rt. LC/MS indicated the reaction was complete. The mixture was filtered through a pad of celite to remove the solids and was concentrated under reduced pressure. The residue was diluted with 5 mL of THF. To the cloudy solution was added tetrabutylammonium fluoride hydrate (0.152 g, 0.545 mmol). The mixture was stirred at rt for 2 hours, LC/MS indicated the reaction was complete. The mixture was diluted with water (15 mL) and extracted with ethyl acetate (315 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by prep HPLC to give (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-(4-carboxyphenyl)-4,4,6a,6b,13b-pentamethyl-2-oxo-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carboxylic acid as a white solid (7.0 mg, 54.9%). MS m/e 576.36 (M+H).sup.+, 2.94 min (method 5B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 8.11-7.94 (m, 2H), 7.35-7.18 (m, 2H), 4.66 (s, 1H), 4.54 (s, 1H), 3.45 (d, J=11.8 Hz, 1H), 3.34 (m, 1H), 2.99 (td, J=10.7, 4.8 Hz, 1H), 2.43-2.29 (m, 1H), 2.23 (d, J=12.3 Hz, 1H), 1.98-1.81 (m, 2H), 1.70 (d, J=13.3 Hz, 1H), 1.66 (s, 3H), 1.63-1.00 (m, 15H), 1.24 (s, 3H), 1.21-1.15 (m, 3H), 1.12 (s, 3H), 1.06-1.00 (m, 6H).

Example 23

Preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid

[0492] ##STR00096##

[0493] Step 1: Preparation of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde.

[0494] To a solution of oxalyl chloride (0.421 ml, 0.842 mmol) in dichloromethane (5.0 ml) at 70 C. was added dropwise a solution of DMSO (0.075 ml, 1.052 mmol) in dichloromethane (5 ml). The mixture was warmed to 50 C. and a solution of ((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-8a-yl)methanol (300 mg, 0.701 mmol) in dichloromethane (2.0 ml) was added dropwise. The mixture was stirred for 15 min at 50 C. then Et.sub.3N (0.293 ml, 2.104 mmol) was added dropwise and the mixture was slowly warmed to rt. The reaction mixture was diluted with dichloromethane (50 ml) and was washed with H.sub.2O (250 ml) followed by brine (50 ml). The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo. The crude product (305 mg) was used with no additional purification. MS m/e 426.24 (M+H).sup.+, 2.32 min (method 2B).

[0495] Step 2: Preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid. (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde (70 mg, 0.164 mmol) and 3,3-dimethyldihydrofuran-2,5-dione (42.1 mg, 0.329 mmol) in dichloromethane (3.0 mL) was added TEA (0.023 mL, 0.164 mmol) followed by DMAP (20.09 mg, 0.164 mmol). The mixture was stirred overnight, then diluted with ethyl acetate (10 mL) and washed with water (10 ml). The organic phase was collected and dried over sodium sulfate. The filtrate was evaporated after filtration and the resulting solid was used in the next step with no additional purification. MS m/e 554.23 (M+H).sup.+, 2.80 min (method 2B).

[0496] Step 3: To a solution of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid (91 mg, 0.164 mmol) in DCE (2 mL) was added acetic acid (0.0940, 1.640 mol) and 4-(3-aminopropyl)thiomorpholine 1,1-dioxide (63.1 mg, 0.328 mmol). The mixture was stirred for 10 minutes at which point it became clear then was stirred at rt for 2 h. To the the mixture was added sodium triacetoxyborohydride (174 mg, 0.820 mmol) and it was stirred overnight at rt. The mixture was diluted with 7 mL of sat. sodium bicarbonate and was extracted with dichloromethane (37 mL). The combined organic layers were dried with over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by prep HPLC. The fractions containing product were collected and concentrated in vacuo to give 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as a white solid (7 mg, 4.09%). MS m/e 730.23 (M+H).sup.+, 2.29 min (method 2B). .sup.1H NMR (400 MHz, CDCl.sub.3) 4.70 (s, 1H), 4.62 (s, 1H), 3.56-3.43 (m, 1H), 3.39-3.25 (m, 1H), 3.21-2.95 (m, 10H), 2.87-2.33 (m, 6H), 2.29-2.10 (m, 1H), 2.00-0.88 (m, 48H).

Example 24

Preparation of 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-3,3-dimethyl-5-oxopentanoic acid

[0497] ##STR00097##

[0498] Step 1: Preparation of 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-3,3-dimethyl-5-oxopentanoic acid. The title compound was prepared in 100% yield following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, using 4,4-dimethyldihydro-2H-pyran-2,6(3H)-dione instead of 3,3-dimethyldihydrofuran-2,5-dione as the reactant. MS: m/e 568.12 (M+H).sup.+, 2.79 min (method 2B).

[0499] Step 2: 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-3,3-dimethyl-5-oxopentanoic acid was prepared in 19.67% yield following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid using 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-3,3-dimethyl-5-oxopentanoic acid instead of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 744.32 (M+H).sup.+, 2.31 min (method 2B). .sup.1H NMR (400 MHz, CDCl.sub.3-d) 4.75-4.65 (m, 1H), 4.62 (s, 1H), 3.68-3.53 (m, 1H), 3.41-3.27 (m, 1H), 3.05 (d, J=8.5 Hz, 8H), 2.94-2.75 (m, 3H), 2.66-2.56 (m, 2H), 2.50-2.24 (m, 6H), 2.05-0.75 (m, 48H).

Example 25

5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2,2-dimethyl-5-oxopentanoic acid

[0500] ##STR00098##

[0501] Step 1: Preparation of 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-5-oxopentanoic acid.

[0502] The title compound was prepared in 11.87% yield following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, using 3,3-dimethyldihydro-2H-pyran-2,6(3H)-dione instead of 3,3-dimethyldihydrofuran-2,5-dione as the reactant. MS: m/e 568.55 (M+H).sup.+, 2.74 min (method 2B). .sup.1H NMR (400 MHz, CDCl.sub.3) 9.68 (d, J=1.5 Hz, 1H), 4.78 (d, J=1.8 Hz, 1H), 4.70-4.57 (m, 1H), 3.51-3.36 (m, 1H), 3.34-3.20 (m, 1H), 2.90 (td, J=11.1, 5.9 Hz, 1H), 2.41-2.23 (m, 2H), 2.16-2.01 (m, 2H), 1.72 (s, 3H), 1.97-1.61 (m, 6H), 1.48 (s, 3H), 1.40 (s, 3H), 1.23 (s, 6H), 1.00 (s, 3H), 0.97 (s, 3H), 0.96 (s, 3H), 1.56-0.89 (m, 16H).

[0503] Step 2: 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2,2-dimethyl-5-oxopentanoic acid was prepared in 21.75% yield following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, step 3, using 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-5-oxopentanoic acid instead of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 744.63 (M+H).sup.+, 2.28 min (method 2B). .sup.1H NMR (400 MHz, CDCl.sub.3) 4.71 (s, 1H), 4.61 (s, 1H), 3.42 (d, J=13.8 Hz, 1H), 3.27 (br. s., 1H), 3.05 (d, J=10.3 Hz, 8H), 2.93-2.75 (m, 3H), 2.63 (t, J=6.5 Hz, 2H), 2.43 (d, J=12.0 Hz, 2H), 2.27 (d, J=7.0 Hz, 2H), 1.69 (s, 3H), 1.48 (s, 3H), 1.40 (s, 3H), 1.17 (s, 6H), 1.06 (s, 3H), 1.00 (s, 3H), 0.96 (s, 3H), 2.06-0.90 (m, 26H).

Example 26

Preparation of 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetic acid

[0504] ##STR00099##

Preparation of 2-(1-(2-methoxy-2-oxoethyl)cyclopentyl)acetic acid

[0505] ##STR00100##

[0506] 8-oxaspiro[4.5]decane-7,9-dione (2.8 g, 16.65 mmol) was dissolved in sodium methoxide in methanol (66.6 ml, 33.3 mmol) then was brought to reflux for 3 hours. The resulting reaction mixture was cooled to room temperature then poured into an ice-water mixture and adjusted pH=2. The mixture was extracted with ether (2100 ml) and the combined organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The expected product was isolated as a light yellow oil (2.6 g, 70%). .sup.1H NMR (400 MHz, CDCl.sub.3) 3.69 (s, 3H), 2.61 (s, 4H), 1.88-1.27 (m, 8H).

[0507] Step 1: Preparation of methyl 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetate.

[0508] The title compound was prepared in 48.5% yield following the procedure described above for preparation of tert-butyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoate, using 2-(1-(2-methoxy-2-oxoethyl)cyclopentyl)acetic acid instead of 4-tert-butoxy-3,3-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 608.46 (M+H).sup.+, 3.35 min (method 4B). .sup.1H NMR (400 MHz, CDCl.sub.3) 9.68 (s, 1H), 4.78 (d, J=1.8 Hz, 1H), 4.69-4.60 (m, 1H), 3.67-3.57 (m, 3H), 3.53-3.40 (m, 1H), 3.31-3.15 (m, 1H), 2.90 (td, J=11.1, 5.9 Hz, 1H), 2.73-2.42 (m, 4H), 2.21-0.73 (m, 48H).

[0509] Step 2: Preparation of methyl 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetate

[0510] The title compound was prepared in 77.5% yield following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, step 3, using methyl 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetate instead of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 784.70 (M+H).sup.+, 2.50 min (method 4B).

[0511] Step 3: To a solution of methyl 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetate (90 mg, 0.115 mmole) in 1,4-dioxane (3 ml) was added a 1N sodium hydroxide solution (0.5 ml, 0.500 mmol). The reaction was heated to 63 C. for 4 hrs. then 25 mg of solid sodium hydroxide was added to the solution and the mixture was again heated for an additional 3 hours. The mixture was cooled to rt and purified by prep HPLC. The fractions containing product were collected and concentrated in vacuo to give 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetic acid as a white solid (24 mg, 27.0%). MS m/e 770.57 (M+H).sup.+, 2.22 min (method 4B). .sup.1H NMR (400 MHz, CDCl.sub.3) 4.70 (s, 1H), 4.63 (s, 1H), 3.65-3.53 (m, 1H), 3.42-3.29 (m, 1H), 3.12-2.90 (m, 11H), 2.68-2.33 (m, 8H), 1.69 (s, 3H), 1.54 (s, 3H), 1.42 (s, 3H), 1.06 (s, 3H), 0.99 (s, 3H), 0.98 (s, 3H), 1.95-0.89 (m, 32H).

Example 27

Preparation of 2-(3-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)phenyl)acetic acid

[0512] ##STR00101##

[0513] Step 1: Preparation of 2-(3-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)phenyl)acetic acid

[0514] The title compound was prepared in 70.7% yield following the procedure described above for preparation of tert-butyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoate, using 1,3-phenylenediacetic acid instead of 4-tert-butoxy-3,3-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 602.39 (M+H).sup.+, 1.69 min (method 4B).

[0515] Step 2: 2-(3-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)phenyl)acetic acid was prepared in 9.75% yield following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, step 3, using 2-(3-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)phenyl)acetic acid instead of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 778.55 (M+H).sup.+, 2.11 min (method 4B). .sup.1H NMR (400 MHz, CDCl.sub.3) 7.26-7.20 (m, 1H), 7.16 (d, J=7.3 Hz, 1H), 7.13 (s, 1H), 7.03 (d, J=7.5 Hz, 1H), 4.69 (s, 1H), 4.62 (s, 1H), 3.66 (br. s., 2H), 3.52 (s, 2H), 3.45-3.40 (m, 1H), 3.30-3.21 (m, 1H), 3.09-2.85 (m, 11H), 2.66-2.32 (m, 4H), 1.99-1.74 (m, 5H), 1.68 (s, 3H), 1.53 (s, 3H), 1.42 (s, 3H), 1.02 (s, 3H), 0.97 (s, 3H), 0.88 (s, 3H), 1.73-0.84 (m, 19H).

Example 28

Preparation of 4-(3-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-3-oxopropyl)benzoic acid

[0516] ##STR00102##

[0517] Step 1: Preparation of 4-(3-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-3-oxopropyl)benzoic acid.

[0518] The title compound was prepared in 70.0% yield following the procedure described above for preparation of tert-butyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoate, using 4-(2-carboxyethyl)benzoic acid instead of 4-tert-butoxy-3,3-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 602.39 (M+H).sup.+, 1.85 min (method 4B).

[0519] Step 2: 4-(3-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-3-oxopropyl)benzoic acid was prepared in 4.2% yield following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, step 3, using 4-(3-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-3-oxopropyl)benzoic acid instead of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 778.55 (M+H).sup.+, 2.16 min (method 4B). .sup.1H NMR (400 MHz, CDCl.sub.3) 7.92 (d, J=8.0 Hz, 2H), 7.25 (d, J=8.3 Hz, 2H), 4.71 (s, 1H), 4.63 (br. s., 1H), 3.39-2.80 (m, 14H), 2.72-2.33 (m, 7H), 2.02-1.79 (m, 5H), 1.69 (s, 3H), 1.48 (s, 3H), 1.38 (s, 3H), 1.04 (s, 3H), 0.96 (s, 3H), 0.90 (s, 3H), 1.75-0.87 (m, 19H).

Example 29

Preparation of 4-((E)-3-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-3-oxoprop-1-en-1-yl)benzoic acid

[0520] ##STR00103##

[0521] Step 1: Preparation of 4-((E)-3-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-3-oxoprop-1-en-1-yl)benzoic acid

[0522] The title compound was prepared in 71.0% yield following the procedure described above for preparation of tert-butyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoate, using (E)-4-(2-carboxyvinyl)benzoic acid instead of 4-tert-butoxy-3,3-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 600.37 (M+H).sup.+, 1.85 min (method 4B).

[0523] Step 2: 4-((E)-3-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-3-oxoprop-1-en-1-yl)benzoic acid was prepared in 20.9% yield following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahdro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, step 3, using 4-((E)-3-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-3-oxoprop-1-en-1-yl)benzoic acid instead of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 776.69 (M+H).sup.+, 2.79 min (method 6B). .sup.1H NMR (400 MHz, METHANOL-d.sub.4) 8.05 (d, J=8.5 Hz, 2H), 7.70 (d, J=8.3 Hz, 2H), 7.42 (d, J=15.6 Hz, 1H), 7.07 (d, J=15.6 Hz, 1H), 4.78 (s, 1H), 4.68 (s, 1H), 3.78-3.64 (m, 1H), 3.58-3.43 (m, 1H), 3.29-3.16 (m, 11H), 2.92-2.82 (m, 3H), 2.61-2.47 (m, 1H), 2.15-1.96 (m, 3H), 1.75 (s, 3H), 1.59 (s, 3H), 1.48 (s, 3H), 1.17 (s, 3H), 1.10 (s, 3H), 1.09 (s, 3H),1.95-1.07 (m, 21H).

Example 30

Preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-3-carbonyl)benzoic acid

[0524] ##STR00104##

[0525] Step 1: Preparation of methyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-3-carbonyl)benzoate

[0526] The title compound was prepared in 72.4% yield following the procedure described above for preparation of tert-butyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoate, using 4-(methoxycarbonyl)benzoic acid instead of 4-tert-butoxy-3,3-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 588.38 (M+H).sup.+, 2.04 min (method 4B).

[0527] Step 2: Preparation of methyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-3-carbonyl)benzoate.

[0528] The title compound was prepared in 27.8% yield following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, step 3, using methyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-3-carbonyl)benzoate instead of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 764.50 (M+H).sup.+, 2.23 min (method 4B).

[0529] Step 3: 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahdro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-3-carbonyl)benzoic acid was prepared in 25.7% yield following the procedure described above for preparation 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetic acid in step 3, using methyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahdro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-3-carbonyl)benzoate instead of methyl 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetate as the reactant. MS: m/e 750.51 (M+H).sup.+, 2.20 min (method 3B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 8.10 (d, J=8.3 Hz, 2H), 7.58-7.41 (m, 2H), 4.77 (s, 1H), 4.65 (s, 1H), 3.49-3.45 (m, 9H), 3.30-3.12 (m, 4H), 3.01-2.82 (m, 3H), 2.65-2.44 (m, 1H), 2.17-2.00 (m, 3H), 1.73 (s, 3H), 1.65 (s, 3H), 1.54 (s, 3H), 1.20 (s, 3H), 1.18 (s, 3H), 1.08 (s, 3H),1.89-1.03 (m, 21H).

Example 31

Preparation of 4-(((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)methyl)benzoic acid

[0530] ##STR00105##

[0531] Step 1: Preparation of methyl 4-(((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)methyl)benzoate.

[0532] The title compound was prepared and used without purification following the procedure described above for (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-allyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde, using methyl 4-(bromomethyl)benzoate instead of 3-bromoprop-1-ene as the reactant. MS: m/e 574.56 (M+H).sup.+, 2.35 min (method 2B).

[0533] Step 2: Preparation of methyl 4-(((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)methyl)benzoate.

[0534] The title compound was prepared and used without purification following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahdro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, step 3, using methyl 4-(((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)methyl)benzoate instead of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 750.45 (M+H).sup.+, 1.86 min (method 3B).

[0535] Step 3: 4-(((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)methyl)benzoic acid was prepared in 16.38% yield following the procedure described above for preparation 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetic acid in step 3, using methyl 4-(((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)methyl)benzoate instead of methyl 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetate as the reactant. MS: m/e 736.61(M+H).sup.+, 1.73 min (method 2B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 8.07-7.97 (m, 2H), 7.53-7.45 (m, 2H), 4.75 (s, 1H), 4.64 (s, 1H), 3.29-3.00 (m, 13H), 2.93 (m, 1H), 2.81 (d, J=12.8 Hz, 1H), 2.68 (t, J=6.5 Hz, 2H), 2.52 (d, J=6.8 Hz, 2H), 2.12-2.00 (m, 1H), 1.72 (s, 3H), 1.62 (s, 3H), 1.36 (s, 3H), 1.18 (s, 3H), 1.07 (s, 6H),1.86-1.03 (m, 23H).

Example 32

Preparation of (E)-4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-4-oxobut-2-enoic acid

[0536] ##STR00106##

[0537] Step 1: Preparation of (E)-4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-4-oxobut-2-enoic acid.

[0538] The title compound was prepared and used without purification following the procedure described above for preparation of tert-butyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahdro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoate, using fumaric acid instead of 4-tert-butoxy-3,3-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 524.25 (M+H).sup.+, 2.64 min (method 4B).

[0539] Step 2. (E)-4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-4-oxobut-2-enoic acid compound was prepared in 20.9% yield following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, step 3, using (E)-4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-4-oxobut-2-enoic acid instead of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 700.48 (M+H).sup.+, 2.12 min (method 3B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 7.00 (d, J=15.6 Hz, 1H), 6.56 (d, J=15.3 Hz, 1H), 4.77 (s, 1H), 4.67 (s, 1H), 3.62 (dd, J=14.6, 4.3 Hz, 1H), 3.51-3.37 (m, 1H), 3.27-3.09 (m, 7H), 3.04 (d, J=3.5 Hz, 4H), 2.83 (d, J=12.8 Hz, 1H), 2.68 (t, J=6.5 Hz, 2H), 2.53 (d, J=5.5 Hz, 1H), 2.16-2.00 (m, 1H), 1.74 (s, 3H), 1.56 (s, 3H), 1.43 (s, 3H), 1.15 (s, 3H), 1.08 (s, 3H), 1.06 (s, 3H),1.98-1.02 (m, 23H).

Example 33

Preparation of 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)acetic acid

[0540] ##STR00107##

[0541] Step 1: Preparation of methyl 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)acetate

[0542] The title compound was prepared and without purification following the procedure described above for (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-allyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde, using methyl 2-bromoacetate instead of 3-bromoprop-1-ene as the reactant. MS: m/e 498.29 (M+H).sup.+, 2.07 min (method 4B).

[0543] Step 2: Preparation of methyl 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)acetate.

[0544] The title compound was prepared in a 42.1% yield by following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahdro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, step 3, using methyl 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)acetate instead of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 674.55 (M+H).sup.+, 1.68 min (method 2B). .sup.1H NMR (400 MHz, chloroform-d) 4.70 (s, 1H), 4.61 (s, 1H), 3.73 (s, 3H), 3.51 (br. s., 2H), 3.13-2.98 (m, 9H), 2.93-2.51 (m, 7H), 2.49-2.37 (m, 1H), 1.71 (s, 3H), 1.12 (s, 3H), 1.05 (s, 3H), 0.96 (s, 3H), 0.88 (s, 3H), 0.84 (s, 3H), 2.02-0.77 (m, 24H).

[0545] Step 3. 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)acetic acid was prepared in 44.5% yield following the procedure described above for preparation 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetic acid in step 3, using 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)acetate instead of methyl 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetate as the reactant. MS: m/e 660.46 (M+H).sup.+, 1.45 min (method 4B). .sup.1H NMR (400 MHz, chloroform-d) 4.66 (s, 1H), 4.59 (s, 1H), 3.73 (d, J=12.8 Hz, 1H), 3.34 (d, J=1.8 Hz, 2H), 3.28 (d, J=13.3 Hz, 1H), 3.18-2.85 (m, 11H), 2.57 (t, J=5.6 Hz, 2H), 2.50 (d, J=12.8 Hz, 1H), 2.36 (br. s., 1H), 1.65 (s, 3H), 1.37 (s, 3H), 1.21 (s, 3H), 1.04 (s, 3H), 0.96 (s, 3H), 0.95 (s, 3H), 1.88-0.92 (m, 24H).

Example 34

Preparation of (E)-ethyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)but-2-enoate

[0546] ##STR00108##

[0547] Step 1: Preparation of (E)-ethyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)but-2-enoate.

[0548] The title compound was prepared and used without purification following the procedure described above for (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-allyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde, using (E)-ethyl 4-bromobut-2-enoate instead of 3-bromoprop-1-ene as the reactant. MS: m/e 538.34 (M+H).sup.+, 2.12 min (method 4B).

[0549] Step 2: Preparation of (E)-ethyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)but-2-enoate.

[0550] The title compound was prepared in 24.5% yield following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, step 3, using (E)-ethyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)but-2-enoate instead of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as the reactant. MS: m/e 714.63 (M+H).sup.+, 1.88 min (method 2B). .sup.1H NMR (400 MHz, chloroform-d) 7.00 (dt, J=15.8, 5.4 Hz, 1H), 6.09-5.95 (m, 1H), 4.71 (s, 1H), 4.63 (s, 1H), 4.22 (quin, J=7.1 Hz, 2H), 3.44 (dd, J=5.4, 1.9 Hz, 1H), 3.18-2.95 (m, 14H), 2.79-2.36 (m, 4H), 2.07-0.81 (m, 45H).

[0551] Step 3. (E)-4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)but-2-enoic acid was prepared in 26.8% yield following the procedure described above for preparation 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetic acid in step 3, using (E)-ethyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)but-2-enoate instead of methyl 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetate as the reactant. MS: m/e 686.48(M+H).sup.+, 1.45 min (method 4B). .sup.1H NMR (400 MHz, chloroform-d) 6.89-6.81 (m, 1H), 6.11 (d, J=15.3 Hz, 1H), 4.70 (s, 1H), 4.62 (s, 1H), 3.18-2.93 (m, 14H), 2.72-2.50 (m, 4H), 2.39 (br. s., 1H), 1.69 (s, 3H), 1.36 (s, 3H), 1.06 (s, 3H), 1.05 (s, 3H), 1.00 (s, 3H), 0.92 (s, 3H), 1.98-0.86 (m, 24H).

Example 35

[0552] ##STR00109##

[0553] Step 1. Preparation of methyl 2-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)acetamido)-2-methylpropanoate

[0554] The title compound was prepared in 78% yield following the procedure described above for preparation of tert-butyl 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoate, using 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)acetic acid and methyl 2-amino-2-methylpropanoate instead of 4-tert-butoxy-3,3-dimethyl-4-oxobutanoic acid and (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde as the reactants. MS: m/e 759.60 (M+H).sup.+, 1.85 min (method 3B).

[0555] Step 2. 2-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)acetamido)-2-methylpropanoic acid was prepared in 36.7% yield following the procedure described above for preparation 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetic acid in step 3, using methyl 2-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)acetamido)-2-methylpropanoate instead of methyl 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetate as the reactant. LC/MS: m/e 745.57 (M+H).sup.+, 1.73 min (method 3B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 4.77 (s, 1H), 4.67 (s, 1H), 3.45 (d, J=17.1 Hz, 1H), 3.21 (d, J=12.8 Hz, 1H), 3.19-3.10 (m, 5H), 3.05 (d, J=5.8 Hz, 4H), 2.84 (d, J=12.8 Hz, 1H), 2.78-2.72 (m, 1H), 2.68 (t, J=6.5 Hz, 3H), 2.61-2.48 (m, 3H), 2.16-2.01 (m, 2H), 1.98-1.81 (m, 5H), 1.75 (s, 3H), 1.79-1.71 (m, 3H), 1.55 (s, 3H), 1.54 (s, 3H), 1.63-1.42 (m, 8H), 1.41-1.20 (m, 4H), 1.16 (s, 3H), 1.12 (s, 6H), 1.20-1.10 (m, 4H), 0.97 (s, 3H), 0.93 (s, 3H).

Example 36

Preparation of 2-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)(methyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)acetamido)-2-methylpropanoic acid

[0556] ##STR00110##

[0557] The title compound was prepared in 19.63% yield following the procedure described above for preparation 24-(3-((((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3,4,4,6a,6b,13b-hexamethyl-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-8a-yl)methyl)(methyl)amino)propyl)thiomorpholine 1,1-dioxide, using 2-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)acetamido)-2-methylpropanoic acid instead of 4-(3-((((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-8a-yl)methyl)amino)propyl)thiomorpholine 1,1-dioxide as the reactant. LC/MS: m/e 759.60 (M+H).sup.+, 1.73 min (method 2B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 4.76 (s, 1H), 4.65 (s, 1H), 3.59 (d, J=16.8 Hz, 1H), 3.18-3.08 (m, 5H), 3.04 (m, 6H), 2.92-2.79 (m, 1H), 2.76 (s, 3H), 2.79-2.69 (m, 2H), 2.65 (t, J=6.7 Hz, 2H), 2.51 (br. s., 1H), 2.11-1.99 (m, 1H), 1.97 (s, 3H), 1.95-1.83 (m, 4H), 1.74 (s, 3H), 1.82-1.67 (m, 4H), 1.60 (m, 1H), 1.55 (s, 3H), 1.54 (s, 3H), 1.57-1.41 (m, 8H), 1.38-1.21 (m, 4H), 1.19-1.13 (m, 2H), 1.18 (s, 3H), 1.15 (s, 3H), 1.10 (s, 3H), 0.99 (s, 3H), 0.98 (s, 3H).

Example 37

Preparation of 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetic acid

[0558] ##STR00111##

[0559] Step 1: Preparation of methyl 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetate

[0560] To a solution of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde (50 mg, 0.117 mmol) in dichloromethane (2 mL) at 0 C., was added methyl 2-chloro-2-oxoacetate (0.021 mL, 0.235 mmol) followed by DIEA (0.062 mL, 0.352 mmol). The resulting solution was stirred for 50 min and then diluted with 20 ml of ethyl acetate, washed with H.sub.2O (210 ml) followed by brine (10 ml). The organic layer was dried over Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure.

[0561] The resulting solid was used without further purification. LC/MS: m/e 512.43 (M+H).sup.+, 2.72 min (method 2B).

[0562] Step 2: Preparation of methyl 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetate

[0563] The title compound was prepared in 55.8% yield following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahdro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, step 3, using methyl 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetate instead of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahdro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as the reactant. LC/MS: m/e 688.47 (M+H).sup.+, 2.23 min (method 2B). .sup.1H NMR (400 MHz, chloroform-d) 4.70 (d, J=2.0 Hz, 1H), 4.61 (d, J=1.3 Hz, 1H), 3.25 (br. s., 2H), 3.04 (q, J=6.5 Hz, 10H), 2.82-2.66 (m, 2H), 2.61 (t, J=7.0 Hz, 2H), 2.43 (dt, J=11.0, 5.5 Hz, 1H), 2.26 (d, J=11.5 Hz, 1H), 2.01-1.85 (m, 2H), 1.85-1.65 (m, 6H), 1.70 (s, 3H), 1.65-1.50 (m, 3H), 1.53 (s, 3H), 1.47 (s, 3H), 1.51-1.30 (m, 8H), 1.31-1.18 (m, 4H), 1.07 (s, 3H), 1.13-1.06 (m, 2H), 1.02 (s, 3H), 1.06-1.00 (m, 1H), 0.99 (s, 3H).

[0564] Step 3. 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetic acid was prepared in 93% yield following the procedure described above for preparation 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetic acid in step 3, using methyl 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetate instead of methyl 2-(1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoethyl)cyclopentyl)acetate as the reactant. LC/MS: m/e 674.57 (M+H).sup.+, 2.10 min (method 2B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 4.77 (s, 1H), 4.66 (s, 1H), 3.51 (br. s., 4H), 3.46-3.35 (br. s., 6H), 3.30-3.15 (m, 3H), 3.09 (br. s., 2H), 2.88 (d, J=13.1 Hz, 1H), 2.52 (d, J=5.5 Hz, 1H), 2.23-2.01 (m, 3H), 1.92-1.69 (m, 7H), 1.74 (s, 3H), 1.69-1.43 (m, 8H), 1.56 (s, 3H), 1.47 (s, 3H), 1.44-1.27 (m, 4H), 1.27-1.11 (m, 2H), 1.15 (s, 3H), 1.08 (s, 3H), 1.07 (s, 3H).

Example 38

Preparation of 2-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetamido)-2-methylpropanoic acid

[0565] ##STR00112##

[0566] Step 1: Preparation of methyl 2-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetamido)-2-methylpropanoate.

[0567] 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetic acid (50 mg, 0.074 mmol) was dissolved in DCM (2 mL) at 0 C., methyl 2-amino-2-methylpropanoate (8.69 mg, 0.074 mmol) was added, followed by HATU (56.4 mg, 0.148 mmol) and DIEA (0.039 mL, 0.223 mmol). The solution was stirred for 3 hours and and aqueous work up followed. The crude material was purified by flash chromatography using a 0-5% methanol in dichloromethane gradient. The title product was isolated as a white foam (0.030 g, 0.039 mmol, 53%). LCMS: m/e 773.6 (M+H).sup.+, 2.13 min (method 8B).

[0568] Step 2: Methyl 2-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetamido)-2-methylpropanoate (60 mg, 0.078 mmol) was dissolved in 1,4-dioxane (1.5 mL) and 1N sodium hydroxide (0.5 ml, 0.500 mmol)) was added. The reaction was stirred for 24 hrs then was purified by prep HPLC. Fractions containing the product were combined and concentrated under reduced pressure to give 2-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetamido)-2-methylpropanoic acid as a white solid (0.040 g, 0.053 mmol, 68%). LCMS: m/e 759.6 (M+H).sup.+, 2.04 min (method 8B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 4.75 (d, J=1.3 Hz, 1H), 4.64 (s, 1H), 3.62-3.52 (m, 5H), 3.46-3.36 (m, 5H), 3.26-3.08 (m, 5H), 2.88 (d, J=12.8 Hz, 1H), 2.51 (td, J=10.5, 5.9 Hz, 1H), 2.20-2.02 (m, 3H), 1.72 (s, 3H), 1.54 (s, 3H), 1.51 (s, 3H), 1.50 (s, 3H), 1.45 (s, 3H), 1.13 (s, 3H), 1.06 (s, 6H), 1.92-1.01 (m, 21H).

Example 39 Preparation of 1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetamido)cyclopropanecarboxylic acid

[0569] ##STR00113##

[0570] Step 1: Preparation of ethyl 1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetamido)cyclopropanecarboxylate.

[0571] 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetic acid (40 mg, 0.059 mmol) in DCM (2 mL) was cooled to 0 C. and ethyl 1-aminocyclopropanecarboxylate (7.67 mg, 0.059 mmol) was added followed by HATU (45.1 mg, 0.119 mmol) and DIEA (0.031 mL, 0.178 mmol). The solution was stirred for 3 hours followed by an aqueous work up. The crude product was purified by flash chromatography using a 0-5% methanol in dichloromethane gradient. The title product was isolated as a white foam (15 mg, 0.019 mmol, 32%). LCMS: m/e 785.6 (M+H).sup.+, 2.2 min (method 8B).

[0572] Step 2: Ethyl 1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetamido)cyclopropanecarboxylate (40 mg, 0.051 mmol) was dissolved in 1,4-dioxane (1.5 mL) and 1N sodium hydroxide (0.5 ml, 0.500 mmol) was added. The reaction was stirred for 24 hrs at rt then was purified by prep HPLC. Fractions containing the product were combined and concentrated under reduced pressure to give 1-(2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-2-oxoacetamido)cyclopropanecarboxylic acid as a white solid (0.020 g, 0.026 mmol, 51%). LCMS: m/e 757.5 (M+H).sup.+, 1.97 min (method 8B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 4.75 (d, J=1.3 Hz, 1H), 4.64 (s, 1H), 3.73-3.62 (m, 1H), 3.51-3.34 (m, 8H), 3.26-3.13 (m, 3H), 3.04 (t, J=7.2 Hz, 2H), 2.87 (d, J=13.1 Hz, 1H), 2.51 (td, J=10.4, 5.6 Hz, 1H), 2.17-2.01 (m, 3H), 1.72 (s, 3H), 1.54 (s, 3H), 1.45 (s, 3H), 1.17 (d, J=3.3 Hz, 2H), 1.14 (s, 3H), 1.06 (s, 6H), 1.91-1.04 (m, 24H).

Example 40

Preparation of 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)nicotinonitrile

[0573] ##STR00114##

[0574] Step 1: Preparation of 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)nicotinonitrile To a mixture of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde (25.0 mg, 0.059 mmol), 6-fluoronicotinonitrile (71.7 mg, 0.587 mmol) and potassium carbonate (16.23 mg, 0.117 mmol) in a sealed tube was added 4 drops of DMSO. The tube was warmed to 130 C. for 3 hours. The reaction mixture was diluted with dichloromethane, washed with water and dried over sodium sulfate. The drying agent was removed by filtration and the filtrate was concentrated under reduced pressure. The crude mixture was purified by flash chromatography and the fractions containing product were collected and concentrated in vacuo to give the title compound as a white solid (29 mg, 94%). LC/MS: m/e 528.39 (M+H).sup.+, 3.07 min (method 4B).

[0575] Step 2: 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)nicotinonitrile was prepared in 24.5% yield following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, step 3, using 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)nicotinonitrile instead of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as the reactant. LC/MS: m/e 704.50 (M+H).sup.+, 2.45 min (method 2B). .sup.1H NMR (500 MHz, chloroform-d) 8.40 (dd, J=2.4, 0.6 Hz, 1H), 7.53 (dd, J=9.1, 2.5 Hz, 1H), 6.67 (d, J=8.8 Hz, 1H), 4.71 (d, J=2.0 Hz, 1H), 4.62 (s, 1H), 3.71-3.59 (m, 1H), 3.59-3.44 (m, 1H), 3.04-3.06 (m, 8H), 2.88-2.69 (m, 3H), 2.62 (t, J=6.9 Hz, 2H), 2.45 (td, J=11.1, 5.6 Hz, 1H), 2.28 (d, J=11.0 Hz, 1H), 2.04-1.87 (m, 2H), 1.87-1.73 (m, 4H), 1.71 (s, 3H), 1.70-1.53 (m, 5H), 1.51 (s, 3H), 1.49 (s, 3H), 1.47-1.39 (m, 6H), 1.39-1.20 (m, 5H), 1.09 (s, 3H), 1.15-1.04 (m, 3H), 1.04-1.00 (m, 3H), 0.98 (s, 3H).

Example 41 and Example 42

Preparation of 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)nicotinamide and 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)nicotinic acid

[0576] ##STR00115##

[0577] To a solution of 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)nicotinonitrile (53 mg, 0.075 mmol) in ethanol (5 mL) was added a 40% w/w solution of potassium hydroxide (10 ml, 60 mmol). The mixture was warmed to 80 C. for 16 hours, then was cooled to rt and neutralized with 6N HCl to pH=4. The mixture was extracted twice with chloroform then the combined organic layers were washed with water and dried over sodium sulfate. The drying agent was removed by filtration and the filtrate was concentrated under reduced pressure. The crude material was purified by prep HPLC. The fractions containing each product were collected and concentrated in vacuo to give the two title compounds as white solids.

Example 41

[0578] (5 mg, 8.74%). MS m/e 722.68 (M+H).sup.+, 1.85 min (method 2B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 8.79 (d, J=2.3 Hz, 1H), 8.39 (dd, J=9.0, 2.3 Hz, 1H), 7.60 (d, J=8.8 Hz, 1H), 4.78 (s, 1H), 4.67 (s, 1H), 4.03 (m, 1H), 3.58 (m, 1H), 3.27 (br. s, 8H), 3.20 (d, J=9.8 Hz, 3H), 2.92-2.84 (m, 2H), 2.53 (br. s., 1H), 2.15-1.93 (m, 4H), 1.93-1.72 (m, 6H), 1.75 (s, 3H), 1.73-1.49 (m, 10H), 1.48 (s, 3H), 1.44 (s, 3H), 1.42-1.30 (m, 3H), 1.27-1.17 (m, 2H), 1.19 (s, 3H), 1.12 (s, 3H), 1.11 (s, 3H).

Example 42

[0579] (45 mg, 79%). LC/MS: m/e 723.51 (M+H).sup.+, 2.04 min (method 2B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 8.79 (d, J=2.0 Hz, 1H), 8.50-8.40 (m, 1H), 7.62 (d, J=9.3 Hz, 1H), 4.78 (d, J=1.5 Hz, 1H), 4.67 (s, 1H), 4.08-3.91 (m, 1H), 3.70-3.58 (m, 1H), 3.54 (dd, J=6.8, 3.5 Hz, 4H), 3.47-3.39 (m, 4H), 3.29-3.23 (m, 1H), 3.21 (dd, J=7.9, 3.1 Hz, 1H), 3.11 (t, J=7.3 Hz, 2H), 2.88 (d, J=13.1 Hz, 1H), 2.53 (td, J=10.5, 5.6 Hz, 1H), 2.22-2.12 (m, 2H), 2.12-2.05 (m, 1H), 2.05-1.94 (m, 1H), 1.94-1.86 (m, 1H), 1.86-1.69 (m, 6H), 1.75 (s, 3H), 1.60-1.70 (m, 6H), 1.58-1.44 (m, 4H), 1.50 (s, 3H), 1.47 (s, 3H), 1.42-1.28 (m, 2H), 1.27-1.15 (m, 2H), 1.18 (s, 3H), 1.11 (s, 3H), 1.09 (s, 3H).

Example 43

Preparation of 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)picolinonitrile

[0580] ##STR00116##

[0581] Step 1: Preparation of 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)picolinonitrile.

[0582] The title compound was prepared in 29% yield following the procedure described above for preparation 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)nicotinonitrile, using 5-fluoropicolinonitrile instead of 6-fluoronicotinonitrile as the reactant. LC/MS: m/e 528.53 (M+H).sup.+, 2.80 min (method 2B). .sup.1H NMR (400 MHz, chloroform-d) 9.69 (d, J=1.5 Hz, 1H), 8.45 (d, J=2.3 Hz, 1H), 7.62-7.55 (m, 1H), 7.47 (dd, J=8.5, 2.5 Hz, 1H), 4.79 (d, J=2.0 Hz, 1H), 4.69-4.61 (m, 1H), 3.57-3.45 (m, 1H), 3.01-2.85 (m, 2H), 2.15-2.02 (m, 2H), 1.98-1.85 (m, 1H), 1.72 (s, 3H), 1.62 (s, 3H), 1.14 (s, 3H), 1.03 (s, 3H), 1.01 (s, 3H), 0.97 (s, 3H), 1.83-0.94 (m, 19H).

[0583] Step 2: 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)picolinonitrile was prepared in 59% yield following the procedure described above for preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid, step 3, using 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)picolinonitrile instead of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2,2-dimethyl-4-oxobutanoic acid as the reactant. LC/MS: m/e 704.57 (M+H).sup.+, 2.33 min (method 2B). .sup.1H NMR (400 MHz, Chloroform-d) 8.44 (d, J=2.3 Hz, 1H), 7.56 (d, J=8.3 Hz, 1H), 7.46 (dd, J=8.4, 2.6 Hz, 1H), 4.70 (d, J=1.8 Hz, 1H), 4.60 (s, 1H), 3.55-3.43 (m, 1H), 3.12-2.91 (m, 10H), 2.82-2.67 (m, 3H), 2.61 (t, J=6.9 Hz, 2H), 2.44 (td, J=11.1, 5.4 Hz, 1H), 2.26 (d, J=11.5 Hz, 1H), 1.98-1.85 (m, 2H), 1.85-1.63 (m, 7H), 1.69 (s, 3H), 1.60-1.36 (m, 8H), 1.36-1.17 (m, 4H), 1.14 (s, 3H), 1.08 (s, 3H), 1.18-0.97 (m, 2H), 1.01 (s, 6H), 1.00 (s, 3H).

Example 44

Preparation of 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)picolinic acid

[0584] ##STR00117##

[0585] The title compound was prepared in 84% yield following the procedure described above for 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)nicotinic acid, using 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)picolinonitrile instead of 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)nicotinonitrile. LC/MS: m/e 723.53 (M+H).sup.+, 1.78 min (method 4B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 8.78 (s, 1H), 8.28 (d, J=8.8 Hz, 1H), 8.25 (dd, J=2.01, 8.8 Hz, 1H), 4.75 (br. s, 1H), 4.63 (br. s, 1H), 4.12 (t, J=11.3 Hz, 1H), 3.58-3.48 (br. s, 4H), 3.45-3.33 (m, 5H), 3.27-3.14 (m, 3H), 3.10 (t, J=7.3 Hz, 2H), 2.85 (d, J=13.1 Hz, 1H), 2.52-2.48 (m, 1H), 2.21-1.98 (m, 3H), 1.96-1.69 (m, 7H), 1.72 (s, 3H), 1.69-1.39 (m, 5H), 1.30 (s, 3H), 1.27 (s, 3H), 1.40-1.24 (m, 8H), 1.21-1.02 (m, 2H), 1.16 (s, 3H), 1.13 (s, 3H), 1.08 (s, 3H).

Example 45

Preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahdro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2-fluorobenzoic acid

[0586] ##STR00118##

[0587] Step 1: Preparation of 2-fluoro-4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]-naphtho[2,1-f]isoquinolin-3-yl)benzonitrile

[0588] A mixture of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde (30 mg, 0.07 mmol) 2,4-difluorobenzonitrile (196 mg, 1.40 mmol) and DIPEA (0.062 ml, 0.35 mmol) in DMSO (0.5 ml) was heated at 180 C. for 4 h. The reaction mixture was cooled to rt, diluted with H.sub.2O (5 ml) and extracted with EtOAc (25 ml). The combined organic layers were washed with H.sub.2O (5 ml), dried over Na.sub.2SO.sub.4, filtered and concentrated in vacuo to give the crude product which was used in next step without further purification. MS m/z 545.47 (M+H).sup.+, 2.53 min (method 7B).

[0589] Step 2: Preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahdro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2-fluorobenzonitrile

[0590] A solution of 2-fluoro-4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)benzonitrile (38 mg, 0.070 mmol), 4-(3-aminopropyl)thiomorpholine 1,1-dioxide (13 mg, 0.070 mmol) and AcOH (8 L, 0.140 mmol) in DCE (2 ml) was stirred at rt for 30 min. Sodium triacetoxyborohydride (74 mg, 0.35 mmol) was added. The resulting mixture was stirred at rt overnight. LC/MS showed the reaction was incomplete. Additional 4-(3-aminopropyl)thiomorpholine 1,1-dioxide (13 mg, 0.070 mmol) and sodium triacetoxyborohydride (74 mg, 0.35 mmol) were added. The reaction was continued at rt for 3 days. The mixture was diluted with 5 ml of saturated NaHCO.sub.3 and extracted with CH.sub.2C.sub.12 (310 ml). The combined organic layers were dried over Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The crude product was purified by flash chromatography to give the title product as a solid. LC/MS m/z 721.64 (M+H).sup.+, 1.86 min (method 7B).

[0591] Step 3: To a solution of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahdro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2-fluorobenzonitrile (10 mg, 0.014 mmol) in EtOH (1 ml) was added KOH (2 ml, 0.014 mmol). The resulting mixture was heated at 80 C. for 4 h, then was cooled to rt. The crude mixture was purified by Prep HPLC. Fractions containing the product were combined and concentrated under reduced pressure to give 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahdro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)-2-fluorobenzoic acid as a solid in 17% yield. .sup.1H NMR (400 MHz, methanol-d.sub.4) 8.08 (t, J=8.2 Hz, 1H), 7.55 (d, J=11.3 Hz, 1H), 7.48 (d, J=8.0 Hz, 1H), 4.76 (s, 1H), 4.65 (s, 1H), 4.18 (t, J=11.8 Hz, 1H), 3.22-3.11 (m, 7H), 3.09-3.03 (m, 4H), 2.86 (d, J=13.6 Hz, 1H), 2.70 (t, J=6.5 Hz, 2H), 2.57-2.47 (m, 1H), 2.10-1.20 (m, 27H), 1.73 (s, 3H), 1.28 (s, 6H), 1.18 (s, 3H), 1.16 (s, 3H), 1.10 (s, 3H). LC/MS m/z 740.67 (M+H).sup.+, 1.28 min (method 7B).

Example 46

Preparation of 4-(3-((((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-3-(4-nitrophenyl)-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-8a-yl)methyl)amino)propyl)thiomorpholine 1,1-dioxide

[0592] ##STR00119##

[0593] Step 1: Preparation of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-3-(4-nitrophenyl)-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde.

[0594] (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde (150.0 mg, 0.352 mmol), 1-fluoro-4-nitrobenzene (300 mg, 2.126 mmol) and potassium carbonate (97 mg, 0.705 mmol) were added to a seal tube. The mixture was diluted with DMSO (0.6 mL) and the tube was sealed and heated 120 C. for 3 hours. The mixture was cooled to rt, diluted with dichloromethane and water. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography using a 0-5% ethyl acetate/Hexanes gradient. Fractions containing the product were combined and concentrated to give the title compound as a yellow solid (0.029 g, 0.053 mmol, 15%). LCMS: m/e 547.4 (M+H).sup.+, 2.30 min (method 4B).

[0595] Step 2: To a solution of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-3-(4-nitrophenyl)-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde (40 mg, 0.073 mmol) in DCE (2 mL) was added acetic acid (8.37 l, 0.146 mmol) and 4-(3-aminopropyl)thiomorpholine 1,1-dioxide (28.1 mg, 0.146 mmol). The mixture was stirred at rt for 2 h, then to the mixture was added sodium triacetoxyborohydride (78 mg, 0.366 mmol) and it was stirred overnight. The mixture was diluted with 7 mL of sat. sodium bicarbonate and was extracted with dichloromethane (37 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography using a 0%-5% methanol/methylene chloride gradient. The fractions containing the product were combined and concentrated under reduced pressure to give 4-(3-((((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-3-(4-nitrophenyl)-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-8a-yl)methyl)amino)propyl)thiomorpholine 1,1-dioxide as a yellow foam (0.035 g, 0.048 mmol, 66%). LCMS: m/e 723.6 (M+H).sup.+, 1.76 min (method 9B). .sup.1H NMR (400 MHz, chloroform-d) 8.11-8.06 (m, 2H), 7.16-7.08 (m, 2H), 4.70 (d, J=2.0 Hz, 1H), 4.60 (d, J=0.8 Hz, 1H), 3.10-2.98 (m, 9H), 2.79-2.66 (m, 3H), 2.61 (t, J=7.0 Hz, 2H), 2.43 (dt, J=11.0, 5.4 Hz, 1H), 2.24 (d, J=11.5 Hz, 1H), 1.70 (s, 3H), 1.19 (s, 3H), 1.07 (s, 3H), 1.06 (s, 3H), 1.01 (s, 3H), 1.00 (s, 3H), 2.02-0.94 (m, 26H).

Example 47

Preparation of 4-(3-((((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-(4-aminophenyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-8a-yl)methyl)amino)propyl)thiomorpholine 1,1-dioxide

[0596] ##STR00120##

[0597] To a solution of 4-(3-((((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-3-(4-nitrophenyl)-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-8a-yl)methyl)amino)propyl)thiomorpholine 1,1-dioxide (72 mg, 0.100 mmol) in abs. ethanol (9004) at was added tin(II) chloride dihydrate (112 mg, 0.498 mmol) in a single portion. The mixture was warmed to 70-72 C. for one hour. The mixture was diluted with ethyl acetate, washed by basic water and extracted with dichloromethane three times. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography using a 0-7.5% methanol/dichlormethane gradient. The fractions containing the product were combined and concentrated under reduced pressure to give the title product as an off-white solid (0.048 g, 0.069 mmol, 69%). LCMS: m/e 693.7 (M+H).sup.+, 1.63 min (method 3B). .sup.1H NMR (400 MHz, CHLOROFORM-d) 6.99 (d, J=7.8 Hz, 2H), 6.59 (d, J=8.8 Hz, 2H), 4.69 (d, J=2.0 Hz, 1H), 4.59 (s, 1H), 3.55 (br. s., 2H), 3.48-3.38 (m, 1H), 3.05 (d, J=7.0 Hz, 8H), 2.73 (br. s., 4H), 2.61 (t, J=6.9 Hz, 2H), 2.43 (td, J=11.0, 5.6 Hz, 1H), 2.29-2.22 (m, 1H), 1.69 (s, 3H), 1.07 (s, 3H), 1.00 (s, 3H), 0.98 (s, 3H), 0.96 (br. s., 3H), 0.87 (s, 3H), 2.07-0.82 (m, 25H).

Example 48

Preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)benzoic acid

[0598] ##STR00121##

[0599] Step 1: Preparation of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)benzonitrile.

[0600] To a mixture of 4-(3-((((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-(4-aminophenyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-8a-yl)methyl)amino)propyl)thiomorpholine 1,1-dioxide (48 mg, 0.069 mmol) and 0.1M hydrochloric acid (1385 l, 0.139 mmol) cooled to 0 C. was added a solution of sodium nitrite (5.73 mg, 0.083 mmol) in 1 ml of water dropwise. The mixture was stirred for 20 min at 0 C. then was neutralized with saturated aqueous sodium carbonate (14.68 mg, 0.139 mmol) at 0 C. The reaction mixture was added to a solution of nickel(II)potassium cyanide monohydrate (71.7 mg, 0.277 mmol) in 2 ml of NH.sub.3NH.sub.4Cl buffer (pH=10) then was stirred at 50-60 C. for 30 min. The mixture was extracted with dichloromethane three times. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography using a 0-3% methanol/dichloromethane gradient. The fractions containing the product were combined and concentrated under reduced pressure to give the title product. LCMS: m/e 703.7 (M+H).sup.+, 1.87 min (method 3B).

[0601] Step 2: To a solution of 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)benzonitrile (15 mg, 0.021 mmol) in ethanol (1 mL) was added a 40% w/w solution of potassium hydroxide (2 mL, 12.00 mmol). The mixture was warmed to 80 C. for 16 hours then was cooled to rt and purified by prep HPLC. The fractions containing the product were combined and concentrated under reduced pressure to give 4-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)benzoic acid t as a white solid (0.002 g, 0.003 mmol, 14%). LCMS: m/e 722.7 (M+H).sup.+, 1.73 min (method 3B).

Example 49 and Example 50

[0602] The preparation of 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carboxylic acid and 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carboxamide

##STR00122##

[0603] Step 1: Preparation of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-(5-bromopyrimidin-2-yl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde.

[0604] (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde (90.0 mg, 0.211 mmol), 5-bromo-2-fluoropyrimidine (374 mg, 2.114 mmol) and potassium carbonate (58.4 mg, 0.423 mmol) were added to small pressure vessel. The vessel was sealed and warmed to 140 C. for 2 hours. The resulted mixture was diluted with methylene chloride, washed with water, dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude material was purified by flash chromatography using a 0.1-3% ethyl acetate/hexanes gradient. After concentrating the fractions, the title product was isolated as a white solid (0.095 g, 0.163 mmol, 77%). LCMS: m/e 582.4 and 584.4 (M+H).sup.+, 3.82 min (method 8B).

[0605] Step 2: Preparation of 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carbonitrile

[0606] To a mixture of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-(5-bromopyrimidin-2-yl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde (95 mg, 0.163 mmol) and zinc cyanide (0.012 mL, 0.196 mmol) in DMF (2 mL) was added palladium tetrakis (18.84 mg, 0.016 mmol). The mixture was heated to 150 C. for 12 h, then was cooled to rt and washed with dichloromethane. The organic layer was washed with water and then the aqueous was extracted with dichloromethane three times. The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography using a 0-3% ethyl acetate/hexanes gradient. The fractions containing the title product were combined and concentrated to give a white solid (0.031 g, 0.059 mmol, 36%). LCMS: m/e 529.45 (M+H).sup.+, 3.33 min (method 4B).

[0607] Step 3: Preparation of 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carbonitrile.

[0608] To a solution of 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carbonitrile (10 mg, 0.019 mmol) in DCE (2 mL) was added acetic acid (2.163 0.038 mmol) and 4-(3-aminopropyl)thiomorpholine 1,1-dioxide (7.27 mg, 0.038 mmol). The mixture was stirred at rt for 2 h, then to the mixture was added sodium triacetoxyborohydride (20.04 mg, 0.095 mmol). The mixture was stirred at rt overnight then was diluted with 7 mL of saturated sodium bicarbonate and was extracted with dichloromethane (37 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography using a 0%-5% methanol/methylene chloride gradient. Fraction containing the product were combined and concentrated under reduced pressure to give the title compound as a white solid (10 mg, 0.014 mmol, 75%). LCMS: m/e 705.67 (M+H).sup.+, 2.29 min (method 4B).

[0609] Step 4: To a solution of 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carbonitrile (24 mg, 0.034 mmol) in ethanol (1 mL) was added a 40% w/w solution of KOH (2.0 mL, 12.0 mmol). The mixture was warmed to 80 C. for 16 hours then was cooled to rt and purified by prep HPLC. The fractions containing each isolate were concentrated under reduced pressure to provide:

Example 49

[0610] 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carboxylic acid was isolated as a white solid (0.017 g, 0.023 mmol, 69%); LCMS: m/e 724.67 (M+H).sup.+, 2.24 min (method 3B).

Example 50

[0611] 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carboxamide was isolated as a film (0.003 g, 4.15 mol, 12%); LCMS: m/e 723.66 (M+H).sup.+, 2.13 min (method 3B).

Example 51

Preparation of 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)(methyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)picolinic acid

[0612] ##STR00123##

[0613] To a mixture of 5-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)picolinic acid (30 mg, 0.041 mmol) in MeOH (5.0 mL) was added formaldehyde (1.3 mg, 0.041 mmol) and acetic acid (2.4 4, 0.041 mmol). The mixture was stirred at rt for 30 minutes and sodium cyanoborohydride was added (2.6 mg, 0.041 mmol). The reaction was monitored by LC/MS. When product was observed the mixture was purified by prep HPLC to give the title product as a white foam. LCMS: m/e 737.7 (M+H).sup.+, 1.84 min (method 3B).

Example 52

Preparation of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-(5-carboxypyrimidin-2-yl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carboxylic acid

[0614] ##STR00124##

[0615] Step 1: Preparation of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-(5-cyanopyrimidin-2-yl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carboxylic acid.

[0616] To a solution of 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carbonitrile (25 mg, 0.047 mmol) in t-BuOH (0.75 mL) was added 2-methyl-2-butene (0.922 mL, 1.844 mmol). A solution of sodium chlorite (34.2 mg, 0.378 mmol) and sodium phosphate monobasic monohydrate (67.9 mg, 0.492 mmol) in water (0.75 mL) was added dropwise over 10 min. The light-yellow solution was stirred at rt for 30 minutes at which point all starting material had been consumed (monitored by TLC). The mixture was diluted with water (50 mL) and was extracted with ethyl acetate (375 mL). The combined organic layers were washed with brine, dried over magnesium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography using a 0-5% methanol in dichloromethane gradient and a 4 g silica gel column. The fractions containing the product were combined concentrated under reduced pressure to give the title compound (22 mg, 0.040 mmol, 85% yield) as a white solid. LCMS: m/e 545.46 (M+H).sup.+, 3.04 min (method 3B).

[0617] Step 2: To a solution of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-(5-cyanopyrimidin-2-yl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carboxylic acid (13 mg, 0.024 mmol) in ethanol (1 mL) was added a 40% w/w solution of potassium hydroxide (2.0 mL, 12.0 mmol). The mixture was warmed to 80 C. for 2 hours, then was cooled to rt and purified by prep HPLC. The fractions containing the product were combined and concentrated under reduced pressure to give (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-(5-carboxypyrimidin-2-yl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carboxylic acid as a white solid (0.009 g, 0.016 mmol, 67%). LCMS: m/e 564.48 (M+H).sup.+, 2.84 min (method 3B).

Example 53

Preparation of 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-((2-(1,1-dioxidothiomorpholino)ethyl)amino)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carboxylic acid

[0618] ##STR00125##

[0619] Step 1: Preparation of 2-((4aR,6aR,6bR,8aS,11R,11aR,13aR,13bR)-8a-isocyanato-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carbonitrile.

[0620] To a solution of (4aR,6aR,6bR,8aS,11R,11aR,13aR,13bR)-3-(5-cyanopyrimidin-2-yl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carboxylic acid (115 mg, 0.211 mmol) in toluene (8 mL) was added triethylamine (0.059 mL, 0.422 mmol) and diphenylphosphoryl azide (0.068 mL, 0.317 mmol). The mixture was heated to reflux for 1 h then was cooled to rt and concentrated under reduced pressure. The residue was purified by flash chromatography using a 5-10% ethyl acetate/hexanes gradient. The fractions containing the product were combined and concentrated under reduced pressure to give the title product as a white solid (0.090 g, 0.166 mmol, 79%). LCMS: m/e 542.48 (M+H).sup.+, 4.12 min (method 4B).

[0621] Step 2: Preparation of 2-((4aR,6aR,6bR,8aS,11R,11aR,13aR,13bR)-8a-amino-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carbonitrile hydrochloride.

[0622] To a solution of 2-((4aR,6aR,6bR,8aS,11R,11aR,13aR,13bR)-8a-isocyanato-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carbonitrile (90 mg, 0.166 mmol) in THF (300 mL) was added HCl (37%, 41 mL, 496 mmol). The mixture was stirred at rt for 36 hrs. The solvent was removed to give product as off-white foam, which was directly used in the next step without further purification.

[0623] Step 3: Preparation of 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-((2-(1,1-dioxidothiomorpholino)ethyl)amino)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carbonitrile.

[0624] A mixture of 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-amino-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-3H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3-yl)pyrimidine-5-carbonitrile hydrochloride (60 mg, 0.109 mmol), 4-(2-chloroethyl)thiomorpholine 1,1-dioxide hydrochloride (109 mg, 0.467 mmol), potassium phosphate (109 mg, 0.514 mmol) and sodium iodide (52.3 mg, 0.315 mmol) in acetonitrile (5 mL) was heated to 120 C. for 19 hours in a seal tube. The reaction mixture was diluted with methylene chloride (20 ml) and washed with water (20 ml). The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography using a 0-40% acetone/hexanes gradient. The fractions containing the product were combine and concentrated under reduced pressure to give title compound (0.035 g, 0.052 mmol, 44%). LCMS: m/e 677.6 (M+H).sup.+, 2.68 min (method 10B).

[0625] Step 4: To a suspension of 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-((2-(1,1-dioxidothiomorpholino)ethyl)amino)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carbonitrile (35 mg, 0.052 mmol) in ethanol (1 mL) was added a 40% w/w solution of KOH (2.0 mL, 12.0 mmol). The mixture was warmed to 80 C. for 3 hours then was cooled to rt and was purified by prep HPLC. The fractions containing the product were combined and concentrated to give 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-((2-(1,1-dioxidothiomorpholino)ethyl)amino)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyrimidine-5-carboxylic acid (0.020 g, 0.029 mmol, 56%) as a white solid. LCMS: m/e 696.7 (M+H).sup.+, 2.15 min (method 3B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 8.79 (s, 2H), 4.83 (s, 1H), 4.73 (s, 1H), 4.42-4.33 (m, 1H), 3.67-3.55 (m, 1H), 3.27-2.76 (m, 12H), 2.22-2.00 (m, 4H), 1.76 (s, 3H), 1.65 (s, 3H), 1.55 (s, 3H), 1.20 (s, 3H), 1.14 (s, 3H), 1.94-1.08 (m, 19H), 1.03 (s, 3H)

Example 54

Preparation of 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyridazine-3-carboxylic acid

[0626] ##STR00126##

[0627] Step 1: Preparation of 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyridazine-3-carbonitrile. (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde (50 mg, 0.117 mmol), 6-chloropyridazine-3-carbonitrile (164 mg, 1.175 mmol) and potassium carbonate (32.5 mg, 0.235 mmol) were added to a sealable pressure vessel and 4 drops of DMSO was added. The vessel was sealed and heated to 145 C. for 4 hours then was cooled to rt and diluted with dichloromethane and washed with water. The organic layer was dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was purified by flash chromatography. The fractions containing the product were combined and concentrated under reduced pressure to give the title product (0.025 g, 0.047 mmol, 40%) as a white solid. LCMS: m/e 529.5 (M+H).sup.+, 2.51 min (method 3B)

[0628] Step 2: Preparation of 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyridazine-3-carbonitrile.

[0629] To a solution of 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyridazine-3-carbonitrile (25 mg, 0.047 mmol) in DCE (2 mL) was added acetic acid (5.41 l, 0.095 mmol) followed by 4-(3-aminopropyl)thiomorpholine 1,1-dioxide (18.18 mg, 0.095 mmol). The mixture was stirred at rt for 2 h, then sodium triacetoxyborohydride (50.1 mg, 0.236 mmol) was added and the mixture was stirred at rt overnight. The mixture was diluted with 7 mL of sat. sodium bicarbonate and was extracted with dichloromethane (37 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product (0.030 g, 0.043 mmol, 90%) was isolated as a yellow foam and was used in the next step without further purification. LCMS: m/e 705.7 (M+H).sup.+, 2.28 min (method 10B).

[0630] Step 3: To a solution of 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyridazine-3-carbonitrile (24 mg, 0.034 mmol) in ethanol (1 mL) was added a 40% w/w solution of KOH (2.0 mL, 12.0 mmol) and the mixture was warmed to 80 C. for 3 hours. The mixture was cooled to rt and purified by prep HPLC. The fractions containing the expected product were combined and concentrated under reduced pressure to give 6-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)pyridazine-3-carboxylic acid t (0.023 g, 0.032 mmol, 94%) as a yellow solid. LCMS: m/e 724.7 (M+H).sup.+, 2.07 min (method 3B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 8.13 (d, J=9.8 Hz, 1H), 7.78 (d, J=9.8 Hz, 1H), 4.76 (s, 1H), 4.65 (s, 1H), 3.73 (dd, J=8.0, 5.0 Hz, 2H), 3.67-3.59 (m, 4H), 3.47 (br. s., 4H), 3.29-3.13 (m, 5H), 2.86 (d, J=12.5 Hz, 1H), 2.58-2.44 (m, 1H), 2.27-1.98 (m, 3H), 1.73 (s, 3H), 1.58 (s, 3H), 1.58 (s, 3H), 1.14 (br. s., 3H), 1.08 (s, 3H), 1.01 (s, 3H), 1.96-0.96 (m, 21H).

Example 55

Preparation of 3-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-4-hydroxycyclobut-3-ene-1,2-dione

[0631] ##STR00127##

[0632] Step 1: Preparation of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-(2-methoxy-3,4-dioxocyclobut-1-en-1-yl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde.

[0633] To a 1-dram vial was added (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-8aH-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde (20.5 mg, 0.048 mmol) and 3,4-dimethoxycyclobut-3-ene-1,2-dione (26 mg, 0.183 mmol), followed by methanol (1.0 mL). To the mixture was added N,N-diisopropylethylamine (3 l, 0.017 mmol). The solution was stirred at rt overnight then was concentrated under reduced pressure. The crude material was purified by flash chromatography using an ethyl acetate/hexanes gradient. The fractions containing the product were combined and concentrated to give the title compound as a white solid (0.022 g, 0.041 mmol, 85%). LCMS: m/e 536.5 (M+H).sup.+, 5.00 min (method 11B).

[0634] Step 2: Preparation of 3-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-4-methoxycyclobut-3-ene-1,2-dione.

[0635] To a solution of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-3-(2-methoxy-3,4-dioxocyclobut-1-en-1-yl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde (21 mg, 0.039 mmol) in DCE (2 mL) was added acetic acid (4.48 0.078 mmol) and 4-(3-aminopropyl)thiomorpholine 1,1-dioxide (15.07 mg, 0.078 mmol). The mixture was stirred at rt for 2 h, then sodium triacetoxyborohydride (41.5 mg, 0.196 mmol) was added and it was stirred at rt overnight. The mixture was diluted with 7 mL of sat. sodium bicarbonate and was extracted with dichloromethane (37 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was used in the next step without further purification. LCMS: m/e 712.6 (M+H).sup.+, 2.38 min (method 8B).

[0636] Step 3: 3-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)-4-methoxycyclobut-3-ene-1,2-dione dissolved in 0.5 ml of ethanol (0.5 mL) and sodium hydroxide (4.70 mg, 0.118 mmol) was added followed by water (0.500 mL). The suspension was stirred at 90 C. for two hours. The resulting mixture was purified by prep HPLC without work-up. Fractions containing desired product were combined and concentrated to afford the title product as a film (3 mg, 10.97%). LCMS: m/e 698.6 (M+H).sup.+, 2.07 min (method 8B). .sup.1H NMR (400 MHz, methanol-d.sub.4) 4.77 (br. s., 1H), 4.67 (s, 1H), 4.26-4.12 (m, 1H), 3.98-3.80 (m, 1H), 3.31-3.13 (m, 10H), 3.03-2.78 (m, 4H), 2.52-2.49 (m, 1H), 2.18-1.96 (m, 4H), 1.74 (s, 3H), 1.52 (s, 3H), 1.51 (s, 3H), 1.16 (s, 3H), 1.09 (s, 3H), 1.05 (s, 3H), 1.91-0.95 (m, 20H).

Example 56

Preparation of 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)thiazole-5-carboxylic acid

[0637] ##STR00128##

[0638] Step 1: Preparation of ethyl 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)thiazole-5-carboxylate. To a solution of (4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinoline-8a-carbaldehyde (40 mg, 0.094 mmol) in DMF (2 mL) in a small resealable tube was added the stated amount of ethyl 2-bromothiazole-5-carboxylate (222 mg, 0.940 mmol) and the stated amount of N-ethyl-N-isopropylpropan-2-amine (450 4, 0.094 mmol). The solution was chilled to 78 C. followed by purging with nitrogen after evacuation to 30 micron Hg. The tube was sealed and warmed to 115 C. for 16 hours. An addition of the bromide and of the base were added and the tube sealed and returned to oil bath at 125 C. for 24 hours. The remaining of the bromide was added and the reaction was allowed to proceed at 130 C. for 2 days. The solvent was removed under reduced pressure at 40 C. and the residue was purified by flash chromatography using a 0-20% ethyl acetate/hexanes gradient and a 25 g silica gel cartridge. The fractions containing the product were combined and concentrated under reduced pressure to give the title product as a pale, glassy solid (0.006 g, 0.010 mmol, 11%). LCMS: m/e 581.5 (M+H).sup.+, 6.76 min (method 12B).

[0639] Step 2: Preparation of ethyl 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)thiazole-5-carboxylate.

[0640] To a solution of ethyl 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-formyl-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)thiazole-5-carboxylate (3.5 mg, 6.03 mop in DCE (2 mL) was added acetic acid (2 equiv.) and 4-(3-aminopropyl)thiomorpholine 1,1-dioxide (2 equiv). The mixture was stirred at rt for 2 h, then to the mixture was added sodium triacetoxyborohydride (5 equiv.) and the mixture was stirred overnight at rt. The mixture was diluted with 7 mL of sat. sodium bicarbonate and was extracted with dichloromethane (37 mL). The combined organic layers were dried over sodium sulfate, filtered and concentrated under reduced pressure. The crude product was purified by pipet column, using a 0-8% ethyl acetate/hexanes gardient followed by a 0.5-6% methanol/dichloromethane gradient. Fractions containing the product were combined and concentrated under reduced pressure to give the title compound. LCMS: m/e 757.7 (M+H).sup.+, 2.52 min (method 10B).

[0641] Step 3: To a solution of ethyl 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)thiazole-5-carboxylate (151 g, 0.002 mmol) in dioxane (1 mL) was added sodium hydroxide (0.2 mL, 0.200 mmol). The mixture was warmed to 70 C. for 3 hours then the solvent was removed. The solid that remained was collected by filtration and washed with water to give 2-((4aR,6aR,6bR,8aS,11R,11aR,11bR,13aR,13bR)-8a-(((3-(1,1-dioxidothiomorpholino)propyl)amino)methyl)-4,4,6a,6b,13b-pentamethyl-11-(prop-1-en-2-yl)hexadecahydro-1H-cyclopenta[5,6]naphtho[2,1-f]isoquinolin-3(2H,4H,13bH)-yl)thiazole-5-carboxylic acid as a white solid (1.0 mg, 1.372 mol, 69%). LCMS: m/e 729.6 (M+H).sup.+, 2.09 min (method 10B).

[0642] Biology Data for the Examples

[0643] M means micromolar;

[0644] mL means milliliter;

[0645] l means microliter;

[0646] mg means milligram;

[0647] g means microgram;

[0648] The materials and experimental procedures used to obtain the results reported in Table 1 are described below.

[0649] HIV cell culture assayMT-2 cells and 293T cells were obtained from the NIH AIDS Research and Reference Reagent Program. MT-2 cells were propagated in RPMI 1640 media supplemented with 10% heat inactivated fetal bovine serum, 100 g/ml penicillin G and up to 100 units/ml streptomycin. The 293T cells were propagated in DMEM media supplemented with 10% heat inactivated fetal bovine serum (FBS), 100 units/ml penicillin G and 100 g/ml streptomycin. The proviral DNA clone of NL.sub.4-3 was obtained from the NIH AIDS Research and Reference Reagent Program. A recombinant NL.sub.4-3 virus, in which a section of the nef gene from NL.sub.4-3 was replaced with the Renilla luciferase gene, was used as a reference virus. In addition, residue Gag P373 was converted to P373S. Briefly, the recombinant virus was prepared by transfection of the altered proviral clone of NL.sub.4-3. Transfections were performed in 293T cells using LipofectAMINE PLUS from Invitrogen (Carlsbad, Calif.), according to manufacturer's instruction. The virus was titered in MT-2 cells using luciferase enzyme activity as a marker. Luciferase was quantitated using the Dual Luciferase kit from Promega (Madison, Wis.), with modifications to the manufacturer's protocol. The diluted Passive Lysis solution was pre-mixed with the re-suspended Luciferase Assay Reagent and the re-suspended Stop & Glo Substrate (2:1:1 ratio). Fifty (50) L of the mixture was added to each aspirated well on assay plates and luciferase activity was measured immediately on a Wallac TriLux (Perkin-Elmer). Antiviral activities of inhibitors toward the recombinant virus were quantified by measuring luciferase activity in cells infected for 4-5 days with NLRluc recombinants in the presence serial dilutions of the inhibitor. The EC.sub.50 data for the compounds is shown in Table 1.

TABLE-US-00002 TABLE 1 Example EC.sub.50 # Structure (M) 1 [00129] 2.31 2 [00130] >8.0 3 [00131] >8.0 4 [00132] >8.0 5 [00133] 1.25 6 [00134] 4.0 7 [00135] 0.48 8 [00136] 1.81 9 [00137] 2.76 10 [00138] 0.32 11 [00139] >8.0 12 [00140] >8.0 13 [00141] >8.0 14 [00142] 1.70 15 [00143] >8.0 16 [00144] >8.0 17 [00145] 4.94 18 [00146] 4.2 19 [00147] >8.0 20 [00148] 3.1 21 [00149] >8.0 22 [00150] >3.0 23 [00151] 0.39 24 [00152] 0.12 25 [00153] 0.12 26 [00154] 0.13 27 [00155] 0.3 28 [00156] 0.94 29 [00157] 1.59 30 [00158] 0.11 31 [00159] >3.0 32 [00160] 0.30 33 [00161] >3.0 34 [00162] >3.0 35 [00163] >3.0 36 [00164] 1.3 37 [00165] >3.0 38 [00166] >3.0 39 [00167] >3.0 40 [00168] 0.76 41 [00169] 0.4 42 [00170] 0.003 43 [00171] 0.28 44 [00172] 0.007 45 [00173] 0.02 46 [00174] >0.33 47 [00175] >0.33 48 [00176] 0.005 49 [00177] 0.0007 50 [00178] 0.06 51 [00179] 0.026 52 [00180] 0.062 53 [00181] 0.001 54 [00182] 0.28 55 [00183] 0.25 56 [00184] 0.004

[0650] The disclosure is not limited to the foregoing illustrative examples and the examples should be considered in all respects as illustrative and not restrictive, reference being made to the appended claims, rather than to the foregoing examples, and all changes which come within the meaning and range of equivalency of the claims are therefore intended to be embraced.